WO2020033587A1 - Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use - Google Patents

Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use Download PDF

Info

Publication number
WO2020033587A1
WO2020033587A1 PCT/US2019/045561 US2019045561W WO2020033587A1 WO 2020033587 A1 WO2020033587 A1 WO 2020033587A1 US 2019045561 W US2019045561 W US 2019045561W WO 2020033587 A1 WO2020033587 A1 WO 2020033587A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
chain variable
amino acid
variable domain
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/045561
Other languages
English (en)
French (fr)
Inventor
Gregory P. CHANG
Ann F. CHEUNG
Asya Grinberg
William Haney
Nicolai Wagtmann
Bradley M. LUNDE
Bianka Prinz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dragonfly Therapeutics Inc
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FIEP19847982.6T priority Critical patent/FI3833386T3/fi
Priority to IL280656A priority patent/IL280656B2/en
Priority to KR1020217006243A priority patent/KR102645411B1/ko
Priority to EA202190453A priority patent/EA202190453A1/ru
Priority to MX2021001508A priority patent/MX2021001508A/es
Priority to DK19847982.6T priority patent/DK3833386T5/da
Priority to BR112021002213-9A priority patent/BR112021002213A2/pt
Priority to EP19847982.6A priority patent/EP3833386B1/en
Priority to CA3108794A priority patent/CA3108794A1/en
Priority to US17/265,876 priority patent/US12275791B2/en
Priority to CN201980061436.2A priority patent/CN112770769B/zh
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Priority to SG11202101276QA priority patent/SG11202101276QA/en
Priority to MYPI2021000690A priority patent/MY201987A/en
Priority to JP2021506447A priority patent/JP7431394B2/ja
Priority to ES19847982T priority patent/ES2954851T3/es
Priority to EP23170653.2A priority patent/EP4249067A3/en
Priority to AU2019318425A priority patent/AU2019318425B2/en
Publication of WO2020033587A1 publication Critical patent/WO2020033587A1/en
Anticipated expiration legal-status Critical
Priority to ZA2021/00916A priority patent/ZA202100916B/en
Priority to US19/076,034 priority patent/US20250206827A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the invention relates to multi- specific binding proteins that bind to NKG2D,
  • CD16 CD16
  • HER2 or ErbB2 epidermal growth factor receptor 2
  • Cancer continues to be a significant health problem despite the substantial research efforts and scientific advances reported in the literature for treating this disease.
  • Some of the most frequently diagnosed cancers include prostate cancer, breast cancer, and lung cancer.
  • Prostate cancer is the most common form of cancer in men.
  • Breast cancer remains a leading cause of death in women.
  • Current treatment options for these cancers are not effective for all patients and/or can have substantial adverse side effects.
  • Other types of cancer also remain challenging to treat using existing therapeutic options.
  • Cancer immunotherapies are desirable because they are highly specific and can facilitate destruction of cancer cells using the patient’s own immune system. Fusion proteins such as bi-specific T-cell engagers are cancer immunotherapies described in the literature that bind to tumor cells and T-cells to facilitate destruction of tumor cells. Antibodies that bind to certain tumor- associated antigens and to certain immune cells have been described in the literature. See, e.g., WO 2016/134371 and WO 2015/095412. [0006] Natural killer (NK) cells are a component of the innate immune system and make up approximately 15% of circulating lymphocytes. NK cells infiltrate virtually all tissues and were originally characterized by their ability to kill tumor cells effectively without the need for prior sensitization.
  • NK Natural killer
  • Activated NK cells kill target cells by means similar to cytotoxic T cells - i.e., via cytolytic granules that contain perforin and granzymes as well as via death receptor pathways.
  • Activated NK cells also secrete inflammatory cytokines such as IFN-g and chemokines that promote the recruitment of other leukocytes to the target tissue.
  • NK cells respond to signals through a variety of activating and inhibitory receptors on their surface. For example, when NK cells encounter healthy self-cells, their activity is inhibited through activation of the killer-cell immunoglobulin-like receptors (KIRs). Alternatively, when NK cells encounter foreign cells or cancer cells, they are activated via their activating receptors (e.g ., NKG2D, NCRs, DNAM1). NK cells are also activated by the constant region of some immunoglobulins through CD 16 receptors on their surface. The overall sensitivity of NK cells to activation depends on the sum of stimulatory and inhibitory signals.
  • KIRs killer-cell immunoglobulin-like receptors
  • HER2 (ErbB2) is a transmembrane glycoprotein, which belongs to the epidermal growth factor receptor family. It is a receptor tyrosine kinase and regulates cell survival, proliferation, and growth. HER2 plays an important role in human malignancies.
  • the ERBB2 gene is amplified or overexpressed in approximately 30% of human breast cancers. Patients with HER2-overexpressing breast cancer have substantially lower overall survival rates and shorter disease-free intervals than patients whose cancer does not overexpress HER2. Moreover, overexpression of HER2 leads to increased breast cancer metastasis. Over-expression of HER2 is also known to occur in many other cancer types, including breast, ovarian, esophageal, bladder and gastric cancer, salivary duct carcinoma, adenocarcinoma of the lung and aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma.
  • the invention relates to multi- specific binding proteins that bind to and kill human cancer cells expressing epidermal growth factor receptor 2 (HER2 or ErbB2).
  • the invention provides multi- specific binding proteins that bind to HER2 on a cancer cell and to the NKG2D receptor and CD16 receptor on natural killer cells.
  • Such proteins can engage more than one kind of NK activating receptor, and may block the binding of natural ligands to NKG2D.
  • the proteins can agonize NK cells in humans, and in other species such as rodents and cynomolgus monkeys.
  • the proteins can stimulate T cells in humans, and in other species such as human, rodents and cynomolgus monkeys.
  • the present invention provides a protein (e.g ., a multi- specific binding protein) comprising: (a) a first antigen-binding site comprising an Fab fragment that binds NKG2D; (b) a second antigen-binding site comprising a single-chain variable fragment (scFv) that binds HER2; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16.
  • a protein e.g ., a multi- specific binding protein
  • a protein e.g ., a multi- specific binding protein comprising: (a) a first antigen-binding site comprising an Fab fragment that binds NKG2D; (b) a second antigen-binding site comprising a single-chain variable fragment (scFv) that binds HER2; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third anti
  • the scFv is linked to the antibody Fc domain or a portion thereof sufficient to bind CD 16, or the third antigen-binding site that binds CD 16, via a hinge comprising Ala-Ser. In certain embodiments, the scFv is linked to the antibody Fc domain.
  • the scFv comprises a heavy chain variable domain and a light chain variable domain.
  • the heavy chain variable domain of the scFv forms a disulfide bridge with the light chain variable domain of the scFv.
  • the disulfide bridge is formed between C44 of the heavy chain variable domain and C100 of the light chain variable domain.
  • the light chain variable domain of the scFv is linked to the heavy chain variable domain of the scFv via a flexible linker.
  • the flexible linker comprises the amino acid sequence of SEQ ID NO: 143.
  • the flexible linker consists of the amino acid sequence of SEQ ID NO: 143.
  • the light chain variable domain is positioned to the N-terminus or C- terminus to the heavy chain variable domain. In certain embodiments, the light chain variable domain is positioned to the N-terminus of the heavy chain variable domain.
  • the Fab fragment is linked to the antibody Fc domain or a portion thereof sufficient to bind CD16, or the third antigen-binding site that binds CD16.
  • the first antigen-binding site that binds NKG2D comprises a heavy chain variable domain comprising complementarity-determining region 1 (CDR1), complementarity-determining region 2 (CDR2), and complementarity-determining region 3 (CDR3) sequences represented by the amino acid sequences of SEQ ID NOs: 168, 96, and 169, respectively; and a light chain variable domain comprising CDR1, CDR2, and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 99, 100, and 101, respectively.
  • CDR1 complementarity-determining region 1
  • CDR2 complementarity-determining region 2
  • CDR3 complementarity-determining region 3
  • the first antigen-binding site that binds NKG2D comprises a heavy chain variable domain comprising CDR1, CDR2, and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 95, 96, and 97, respectively; and a light chain variable domain comprising CDR1, CDR2, and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 99, 100, and 101, respectively.
  • a protein of the present invention comprising a first antigen -binding that binds NKG2D, comprises:
  • a heavy chain variable domain comprising complementarity-determining region 1 (CDR1), complementarity-determining region 2 (CDR2), and complementarity determining region 3 (CDR3) sequences represented by the amino acid sequences of SEQ ID NOs: 168, 96, and 169, respectively; and a light chain variable domain comprising CDR1, CDR2, and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 99, 100, and 101, respectively;
  • (k) a heavy chain variable domain comprising CDR1, CDR2, and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 168, 96, and 185, respectively; and a light chain variable domain comprising CDR1, CDR2, and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 99, 100, and 101, respectively; or
  • a second antigen -binding site comprising an scFv that binds HER2, comprises:
  • a heavy chain variable domain comprising CDR1, CDR2, and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 131, 132, and 133, respectively, and a light chain variable domain comprising CDR1, CDR2, and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 135, 136, and 137, respectively.
  • the first antigen-binding site comprises a heavy chain variable domain related to SEQ ID NO:94 and a light chain variable domain related to SEQ ID NO:98.
  • the heavy chain variable domain of the first antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:94, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:95 or 168), CDR2 (SEQ ID NO:96), and CDR3 (SEQ ID NO:97 or 169) sequences of SEQ ID NO:94.
  • the light chain variable domain of the second antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:98, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:99), CDR2 (SEQ ID NO: 100), and CDR3 (SEQ ID NO: 101) sequences of SEQ ID NO:98.
  • the first antigen-binding site comprises a heavy chain variable domain related to SEQ ID NO: 144 and a light chain variable domain related to SEQ ID NO:98.
  • the heavy chain variable domain of the first antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 144, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:95 or 168), CDR2 (SEQ ID NO:96), and CDR3 (SEQ ID NO: 172 or 173) sequences of SEQ ID NO: 144.
  • the light chain variable domain of the second antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:98, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:99), CDR2 (SEQ ID NO: 100), and CDR3 (SEQ ID NO: 101) sequences of SEQ ID NO:98.
  • the first antigen-binding site comprises a heavy chain variable domain related to SEQ ID NO: 174 and a light chain variable domain related to SEQ ID NO:98.
  • the heavy chain variable domain of the first antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 174, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:95 or 168), CDR2 (SEQ ID NO:96), and CDR3 (SEQ ID NO: 175 or 176) sequences of SEQ ID NO: 174.
  • 90% e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
  • the light chain variable domain of the second antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:98, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:99), CDR2 (SEQ ID NO: 100), and CDR3 (SEQ ID NO: 101) sequences of SEQ ID NO:98.
  • the first antigen-binding site comprises a heavy chain variable domain related to SEQ ID NO: 177 and a light chain variable domain related to SEQ ID NO:98.
  • the heavy chain variable domain of the first antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 177, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:95 or 168), CDR2 (SEQ ID NO:96), and CDR3 (SEQ ID NO: 178 or 179) sequences of SEQ ID NO: 177.
  • the light chain variable domain of the second antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:98, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:99), CDR2 (SEQ ID NO: 100), and CDR3 (SEQ ID NO: 101) sequences of SEQ ID NO:98.
  • the first antigen-binding site comprises a heavy chain variable domain related to SEQ ID NO: 180 and a light chain variable domain related to SEQ ID NO:98.
  • the heavy chain variable domain of the first antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 180, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:95 or 168), CDR2 (SEQ ID NO:96), and CDR3 (SEQ ID NO:l8l or 182) sequences of SEQ ID NO: 180.
  • the light chain variable domain of the second antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:98, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:99), CDR2 (SEQ ID NO: 100), and CDR3 (SEQ ID NO: 101) sequences of SEQ ID NO:98.
  • the first antigen-binding site comprises a heavy chain variable domain related to SEQ ID NO: 183 and a light chain variable domain related to SEQ ID NO:98.
  • the heavy chain variable domain of the first antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 183, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:95 or 168), CDR2 (SEQ ID NO:96), and CDR3 (SEQ ID NO: 184 or 185) sequences of SEQ ID NO: 183.
  • 90% e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
  • the light chain variable domain of the second antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:98, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:99), CDR2 (SEQ ID NO: 100), and CDR3 (SEQ ID NO: 101) sequences of SEQ ID NO:98.
  • the first antigen-binding site comprises a heavy chain variable domain related to SEQ ID NO: 186 and a light chain variable domain related to SEQ ID NO:98.
  • the heavy chain variable domain of the first antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 186, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:95 or 168), CDR2 (SEQ ID NO:96), and CDR3 (SEQ ID NO: 187 or 188) sequences of SEQ ID NO: 186.
  • the light chain variable domain of the second antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:98, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:99), CDR2 (SEQ ID NO: 100), and CDR3 (SEQ ID NO: 101) sequences of SEQ ID NO:98.
  • the first antigen-binding site comprises a heavy chain variable domain related to SEQ ID NO:86 and a light chain variable domain related to SEQ ID NO:90.
  • the heavy chain variable domain of the first antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:86, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:87 or 166), CDR2 (SEQ ID NO:88), and CDR3 (SEQ ID NO:89 or 167) sequences of SEQ ID NO:86.
  • the light chain variable domain of the second antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:90, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:9l), CDR2 (SEQ ID NO:92), and CDR3 (SEQ ID NO:93) sequences of SEQ ID NO:90.
  • the first antigen-binding site comprises a heavy chain variable domain related to SEQ ID NO: 102 and a light chain variable domain related to SEQ ID NO: 106.
  • the heavy chain variable domain of the first antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 102, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:7l or 162), CDR2 (SEQ ID NO:72), and CDR3 (SEQ ID NO: 105 or 170) sequences of SEQ ID NO: 102.
  • the light chain variable domain of the second antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 106, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO: 107), CDR2 (SEQ ID NO: 108), and CDR3 (SEQ ID NO: 109) sequences of SEQ ID NO: 106.
  • the first antigen-binding site comprises a heavy chain variable domain related to SEQ ID NO:70 and a light chain variable domain related to SEQ ID NO:74.
  • the heavy chain variable domain of the first antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:70, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:7l or 162), CDR2 (SEQ ID NO:72), and CDR3 (SEQ ID NO:73 or 163) sequences of SEQ ID NO:70.
  • the light chain variable domain of the second antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:74, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:75), CDR2 (SEQ ID NO:76), and CDR3 (SEQ ID NO:77) sequences of SEQ ID NO:74.
  • the first antigen-binding site comprises a heavy chain variable domain related to SEQ ID NO:70 and a light chain variable domain related to SEQ ID NO:74.
  • the heavy chain variable domain of the first antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:70, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:7l or 162), CDR2 (SEQ ID NO:72), and CDR3 (SEQ ID NO:73 or 163) sequences of SEQ ID NO:70.
  • the light chain variable domain of the second antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:74, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:75), CDR2 (SEQ ID NO:76), and CDR3 (SEQ ID NO:77) sequences of SEQ ID NO:74.
  • the first antigen-binding site comprises a heavy chain variable domain related to SEQ ID NO:78 and a light chain variable domain related to SEQ ID NO:82.
  • the heavy chain variable domain of the first antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:78, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:79 or 164), CDR2 (SEQ ID NO:80), and CDR3 (SEQ ID NO:8l or 165) sequences of SEQ ID NO:78.
  • 90% e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
  • the light chain variable domain of the second antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:82, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:75), CDR2 (SEQ ID NO:76), and CDR3 (SEQ ID NO:77) sequences of SEQ ID NO:82.
  • the first antigen-binding site binds to NKG2D with a KD of 2 nM to 120 nM, as measured by surface plasmon resonance.
  • the protein binds to NKG2D with a KD of 2 nM to 120 nM, as measured by surface plasmon resonance.
  • the second antigen-binding site binding to HER2 comprises a heavy chain variable domain related to SEQ ID NO: 195 and a light chain variable domain related to SEQ ID NO: 196.
  • the heavy chain variable domain of the second antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 195, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO: 115), CDR2 (SEQ ID NO: 116), and CDR3 (SEQ ID NO: 117) sequences of SEQ ID NO: 195.
  • the light chain variable domain of the second antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%,
  • the second antigen-binding site binding to HER2 comprises an scFv comprising the amino acid sequence of SEQ ID NO: 139.
  • the second antigen-binding site binding to HER2 comprises a heavy chain variable domain related to SEQ ID NO: 197 and a light chain variable domain related to SEQ ID NO: 198.
  • the heavy chain variable domain of the second antigen binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 197, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO: 123), CDR2 (SEQ ID NO: 124), and CDR3 (SEQ ID NO: 125) sequences of SEQ ID NO: 197.
  • the second antigen-binding site binding to HER2 comprises a heavy chain variable domain related to SEQ ID NO: 199 and a light chain variable domain related to SEQ ID NO:200.
  • the heavy chain variable domain of the second antigen binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 199, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO: 131), CDR2 (SEQ ID NO: 132), and CDR3 (SEQ ID NO: 133) sequences of SEQ ID NO: 199.
  • the light chain variable domain of the second antigen-binding site can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:200, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO: 135), CDR2 (SEQ ID NO: 136), and CDR3 (SEQ ID NO: 137) sequences of SEQ ID NO:200.
  • the second antigen binding site binding to HER2 comprises an scFv comprising the amino acid sequence of SEQ ID NO: 171.
  • the antibody Fc domain comprises an Fc domain comprising an amino acid sequence at least 90% identical to the Fc domain of human IgGl and differs at one or more positions selected from the group consisting of Q347, Y349, T350, L351, S354, E356, E357, K360, Q362, S364, T366, L368, K370, N390, K392, T394, D399, S400, D401, F405, Y407, K409, T411, K439.
  • the antibody Fc domain comprises an Fc domain of a human IgGl comprising T366S, L368A, and Y407V substitutions, e.g., in an Fc domain linked to an scFv.
  • the protein comprises a sequence of SEQ ID NO: 141, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 194, SEQ ID NO: 155, or SEQ ID NO: 148.
  • this sequence represents the heavy chain portion of the Fab fragment linked to the antibody Fc domain.
  • the instant disclosure provides a protein (e.g., a multi- specific binding protein) comprising: (a) a first polypeptide comprising an amino acid sequence at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 141; (b) a second polypeptide comprising an amino acid sequence at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 140, SEQ ID NO: 190, or SEQ ID NO: 192; and (c) a third polypeptide comprising an amino acid sequence at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 142.
  • a protein e.g., a multi-
  • the second polypeptide comprises an amino acid sequence at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 140.
  • the instant disclosure provides a protein (e.g., a multi- specific binding protein) comprising: (a) a first polypeptide comprising an amino acid sequence at least 95% (e.g., 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: l4l; (b) a second polypeptide comprising an amino acid sequence at least 95% (e.g., 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 140, SEQ ID NO: 190, or SEQ ID NO: 192; and (c) a third polypeptide comprising an amino acid sequence at least 95% (e.g., 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 142.
  • the second polypeptide comprises an amino acid sequence at least 95% (e.g., 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 142.
  • the instant disclosure provides a protein (e.g., a multi- specific binding protein) comprising: (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 141; (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 140, SEQ ID NO: 190, or SEQ ID NO: 192; and (c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 142.
  • a protein e.g., a multi- specific binding protein
  • a protein comprising: (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 141; (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 140, SEQ ID NO: 190, or SEQ ID NO: 192; and (c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 142.
  • the protein comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 141; (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 140; and (c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 142.
  • the instant disclosure provides a formulation comprising a protein disclosed herein and a pharmaceutically acceptable carrier.
  • the instant disclosure provides a cell comprising one or more nucleic acids expressing a protein disclosed herein.
  • the instant disclosure provides a method of directly and/or indirectly enhancing tumor cell death, the method comprising exposing a tumor and natural killer cells to a protein disclosed herein.
  • the instant disclosure provides a method of treating cancer, wherein the method comprises administering a protein or a formulation disclosed herein to a patient in need thereof.
  • the cancer is selected from the group consisting of breast cancer, thyroid cancer, gastric cancer, renal cell carcinoma,
  • adenocarcinoma of the lung prostate cancer, cholangiocarcinoma, uterine cancer, pancreatic cancer, colorectal cancer, ovarian cancer, cervical cancer, head and neck cancer, lung squamous, mesothelioma, liver cancer, mesothelioma, sarcoma, and gall bladder cancer.
  • FIG. 1 illustrates a trispecific antibody (TriNKET) that contains an HER2-binding scFv, a NKG2D-targeting Fab, and a heterodimerized antibody constant region/domain (“CD domain”) that binds CD 16 (scFv-Fab format).
  • the Fc domain linked to the Fab fragment comprises mutations of K360E and K409W and the Fc domain linked to the scFv comprises matching mutations Q347R, D399V, and F405T for forming an Fc heterodimer (shown as a triangular lock-and-key format in the Fc domains in FIG. 1).
  • the antibody format is referred herein as F3’-TriNKET.
  • the Fc domain linked to the Fab fragment comprises the mutations of Q347R, D399V, and F405T, and the Fc domain linked to the scFv comprises matching mutations K360E and K409W for forming a heterodimer.
  • FIG. 2 is a representation of a“knob-in-hole” (KiH) TriNKET, which includes an scFv that binds HER2 linked to an Fc domain via a hinge comprising Ala-Ser, and an NKG2D-binding Fab fragment including (a) a heavy chain portion comprising a heavy chain variable domain and a CH1 domain connected to an Fc domain, and (b) a light chain portion comprising a light chain variable domain and a CL domain.
  • KiH a“knob-in-hole”
  • FIG. 4 are line graphs demonstrating HER2-targeted TriNKETs are more potent than trastuzumab on a HER2++ cell line.
  • FIG. 6 shows HER2-targeted TriNKETs outperform trastuzumab in a long-term killing assay.
  • FIG. 7 shows HER2-targeted TriNKETs outperform trastuzumab in a long-term killing assay.
  • FIGs. 8A to 8F are FACS showing that HER2-Targeted TriNKETs show minimal binding to immune cells in human blood.
  • FIG 8A shows that HER2-Targeted TriNKETs show minimal binding to NK cells in human blood
  • FIG. 8B shows that HER2- Targeted TriNKETs show minimal binding to CD8+ T cells
  • FIG. 8C shows that HER2- Targeted TriNKETs show minimal binding to CD4+ T cells
  • FIG. 8D shows that HER2- Targeted TriNKETs show minimal binding to B cells
  • FIG. 8E shows that HER2-Targeted TriNKETs show minimal binding to monocytes
  • FIG. 9 are line graphs demonstrating binding of A49-F3’-TriNKET-Trastuzumab to human cardiomyocytes, SKBR3, H661 and 786-0 cancer cells.
  • FIG. 10A shows that A49-F3’-TriNKET-Trastuzumab-mediated human PBMC killing of SKBR3 cancer after 3 days in co-culture at PBMC to target cell ratio (E:T) of 1:1.
  • FIG. 10B shows that A49-F3’-TriNKET-Trastuzumab does not kill non- malignant healthy cardiomyocytes even after 3 days in co-culture at PBMC to target cell ratio (E:T) of 1:1.
  • FIG. 11A shows A49-F3’-TriNKET-Trastuzumab-mediated human PBMC killing of SKBR3 cancer cells after 3 days in co-culture at PBMC to target cell ratio (E:T) of 20:1.
  • FIG. 11B shows that A49-F3’-TriNKET-Trastuzumab does not kill non- malignant healthy cardiomyocytes even after 3 days in co-culture at PBMC to target cell ratio (E:T) of 20:1.
  • FIGs. 12A to 12B show that CD8+ T cells generated with conA stimulation and cultured with IL-15 were of high purity (99% of CD3+CD8+ cells) (FIG. 12A), and all expressed NKG2D (FIG. 12B), but not CD16 (FIG. 12C).
  • FIGs. 13A to 13B are graphs showing cytotoxic activity of CD8+ T cells in the presence of A49-F3’-TriNKET-Trastuzumab, after culturing with IL-15.
  • FIG. 13A shows enhanced killing of SkBr-3 tumor cells in short-term co-cultures by A49-F3’-TriNKET- Trastuzumab.
  • HER2-targeting A49-F3’-TriNKET-Trastuzumab triggered dose-dependent lysis of SkBr-3 target cells by IL-15 stimulated CD8+ T cell.
  • 13B shows that 67 nM of HER2-targeting TriNKET triggered lysis of SkBr-3 target cells by IL-2 stimulated CD8+ T cell. Dotted line indicates the effect with only CD8+ T cells co-cultured with SkBr-3 tumor cells (untreated).
  • FIG. 14A shows percent growth levels of SkBr-3 cells cultured alone, co-cultured with CD8+ T cells, co-cultured with CD8+ T cells and A49-F3’-TriNKET-Trastuzumab, each in the presence of anti-CD3.
  • FIG. 14B shows percent growth level of SkBr-3 cells cultured alone, co-cultured with CD8+ T cells, co-cultured with CD8+ T cells and A49-F3’-TriNKET-Trastuzumab, each in the absence of anti-CD3.
  • FIGs. 15A to 15B show TriNKET binding to SkBr-3 cell line that has a high level of HER2 expression, as measured by flow cytometry of SkBr-3 cells incubated with a series of concentrations of TriNKET or trastuzumab and a secondary antibody conjugated with a fluorophore.
  • FIG. 15A shows the level of binding as percentage values of median
  • FIG. 15B shows the level of binding as fold over background (FOB) values of MFI relative to the background MFI observed with the cells incubated with the secondary antibody only.
  • FIGs. 16A to 16B show TriNKET binding to NCI-H661 cell line that has a moderate level of HER2 expression, as measured by flow cytometry of NCI-H661 cells incubated with a series of concentrations of TriNKET or trastuzumab and a secondary antibody conjugated with a fluorophore.
  • FIG. 16A shows the level of binding as percentage values of median fluorescence intensity (MFI) relative to the maximum MFI observed with the cells incubated with 670 nM of TriNKET.
  • FIG. 16B shows the level of binding as fold over background (FOB) values of MFI relative to the background MFI observed with the cells incubated with the secondary antibody only.
  • MFI median fluorescence intensity
  • FOB fold over background
  • FIGs. 17A to 17B show TriNKET binding to 786-0 cell line that has a low level of HER2 expression, as measured by flow cytometry of 786-0 cells incubated with a series of concentrations of TriNKET or trastuzumab and a secondary antibody conjugated with a fluorophore.
  • FIG. 16A shows the level of binding as percentage values of median
  • FIG. 16B shows the level of binding as fold over background (FOB) values of MFI relative to the background MFI observed with the cells incubated with the secondary antibody only.
  • FIGs. 18A to 18B show HER2-targeted TriNKETs binding to hNKG2D- expressing EL4 cells, as measured by flow cytometry of EL4 cells incubated with a series of concentrations of TriNKETs or trastuzumab and a secondary antibody conjugated with a fluorophore.
  • the levels of binding are shown as fold over background (FOB) values of MFI relative to the background MFI observed with the cells incubated with the secondary antibody only.
  • FOB fold over background
  • FIG. 19 shows TriNKETs are more potent and effective in mediating NK-cell killing of 786-0 target cells than the combination of Fc-silent TriNKET and trastuzumab.
  • FIG. 20 shows TriNKETs are more potent and effective in mediating NK-cell killing of H661 target cells than the combination of Fc-silent TriNKET and trastuzumab.
  • FIG. 21 is a line graph showing the potency of TriNKET A and TriNKET A* (in which M102 of A49-F3’-TriNKET-Trastuzumab is substituted with I) in mediating cytotoxicity of NK cells against SKBR-3 target cells.
  • the invention provides multi- specific binding proteins that bind HER2 on a cancer cell and the NKG2D receptor and CD 16 receptor on natural killer cells,
  • the term“antigen-binding site” refers to the part of the immunoglobulin molecule that participates in antigen binding.
  • the antigen-binding site is formed by amino acid residues of the N-terminal variable (“V”) regions of the heavy (“H”) and light (“L”) chains.
  • V N-terminal variable
  • L light
  • Three highly divergent stretches within the V regions of the heavy and light chains are referred to as“hypervariable regions” which are interposed between more conserved flanking stretches known as“framework regions,” or “FR.”
  • FR refers to amino acid sequences which are naturally found between and adjacent to hypervariable regions in immunoglobulins.
  • the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen binding surface.
  • the antigen-binding surface is complementary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are referred to as“complementarity-determining regions,” or“CDRs.”
  • CDRs complementary to the three-dimensional surface of a bound antigen
  • the antigen-binding site is formed by a single antibody chain providing a“single domain antibody.”
  • Antigen-binding sites can exist in an intact antibody, in an antigen-binding fragment of an antibody that retains the antigen binding surface, or in a recombinant polypeptide such as an scFv, using a peptide linker to connect the heavy chain variable domain to the light chain variable domain in a single polypeptide. All the amino acid positions in heavy or light chain variable regions disclosed herein are numbered according to Rabat
  • tumor-associated antigen means any antigen including but not limited to a protein, glycoprotein, ganglioside, carbohydrate, or lipid that is associated with cancer. Such an antigen can be expressed on malignant cells or in the tumor
  • microenvironment such as on tumor-associated blood vessels, extracellular matrix, mesenchymal stroma, or immune infiltrates.
  • the CDRs of an antigen-binding site can be determined by the methods described in Rabat et ah, J. Biol. Chem. 252, 6609-6616 (1977) and Rabat et ah, Sequences of protein of immunological interest. (1991), Chothia et ah, J. Mol. Biol. 196:901-917 (1987), and MacCallum et ah, J. Mol. Biol. 262:732-745 (1996).
  • the CDRs determined under these definitions typically include overlapping or subsets of amino acid residues when compared against each other.
  • the term“CDR” is a CDR as defined by
  • CDR is a CDR as defined by Rabat et al., J. Biol. Chem. 252, 6609- 6616 (1977) and Rabat et al., Sequences of protein of immunological interest. (1991).
  • heavy chain CDRs and light chain CDRs of an antibody are defined using different conventions.
  • the heavy chain CDRs are defined according to MacCallum ⁇ supra), and the light CDRs are defined according to Rabat (supra).
  • CDRH1, CDRH2 and CDRH3 denote the heavy chain CDRs
  • CDRL1, CDRL2 and CDRL3 denote the light chain CDRs.
  • the terms“subject” and“patient” refer to an organism to be treated by the methods and compositions described herein. Such organisms preferably include, but are not limited to, mammals (e.g ., murines, simians, equines, bovines, porcines, canines, felines, and the like), and more preferably include humans.
  • the term“effective amount” refers to the amount of a compound (e.g., a compound of the present invention) sufficient to effect beneficial or desired results.
  • an effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route.
  • the term“treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.
  • the term“pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
  • the term“pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents.
  • the compositions also can include stabilizers and preservatives.
  • stabilizers and adjuvants see e.g., Martin, Remington's Pharmaceutical Sciences, l5th Ed., Mack Publ. Co., Easton, PA [1975].
  • the term“pharmaceutically acceptable salt” refers to any pharmaceutically acceptable salt (e.g., acid or base) of a compound of the present invention which, upon administration to a subject, is capable of providing a compound of this invention or an active metabolite or residue thereof.
  • “salts” of the compounds of the present invention may be derived from inorganic or organic acids and bases.
  • Exemplary acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p- sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like.
  • Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their
  • Exemplary bases include, but are not limited to, alkali metal (e.g., sodium) hydroxides, alkaline earth metal (e.g., magnesium) hydroxides, ammonia, and compounds of formula NW 4 + , wherein W is Ci- 4 alkyl, and the like.
  • alkali metal e.g., sodium
  • alkaline earth metal e.g., magnesium
  • W is Ci- 4 alkyl
  • Exemplary salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate,
  • salts include anions of the compounds of the present invention compounded with a suitable cation such as Na + , NH 4 + , and NW 4 + (wherein W
  • salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable.
  • salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
  • compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.
  • compositions specifying a percentage are by weight unless otherwise specified. Further, if a variable is not accompanied by a definition, then the previous definition of the variable controls.
  • the invention provides multi- specific binding proteins that bind HER2 on a cancer cell and the NKG2D receptor and CD 16 receptor on natural killer cells to activate the natural killer cell.
  • the multi- specific binding proteins are useful in the pharmaceutical compositions and therapeutic methods described herein. Binding of the multi- specific binding protein to the NKG2D receptor and CD 16 receptor on natural killer cell enhances the activity of the natural killer cell toward destruction of a cancer cell. Binding of the multi- specific binding protein to HER2 on a cancer cell brings the cancer cell into proximity with the natural killer cell, which facilitates direct and indirect destruction of the cancer cell by the natural killer cell. Further description of exemplary multi- specific binding proteins is provided below.
  • the first component of the multi- specific binding proteins binds to NKG2D receptor-expressing cells, which can include but are not limited to NK cells, NKT cells, gd T cells and CD8 + ab T cells.
  • NKG2D receptor-expressing cells can include but are not limited to NK cells, NKT cells, gd T cells and CD8 + ab T cells.
  • the multi- specific binding proteins may block natural ligands, such as ULBP6 and MICA, from binding to NKG2D and activating NK cells.
  • the second component of the multi- specific binding proteins binds to HER2- expressing cells, which can include but are limited to breast, ovarian, esophageal, bladder and gastric cancer, salivary duct carcinoma, adenocarcinoma of the lung and aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma.
  • the third component for the multi- specific binding proteins binds to cells expressing CD 16, an Fc receptor on the surface of leukocytes including natural killer cells, macrophages, neutrophils, eosinophils, mast cells, and follicular dendritic cells.
  • the multi- specific binding proteins described herein can take various formats.
  • one format involves a heterodimeric, multi-specific antibody including a first immunoglobulin heavy chain, a second immunoglobulin heavy chain and an immunoglobulin light chain (FIG. 1).
  • the first immunoglobulin heavy chain includes a first Fc (hinge-CH2- CH3) domain fused via either a linker or an antibody hinge to an Fab fragment composed of a heavy chain portion comprising a heavy chain variable domain and a heavy chain CH1 domain, and a light chain portion comprising a light chain variable domain and a light chain constant domain (CL), wherein the heavy chain and light chain portions of the Fab fragment pair and bind NKG2D.
  • Fc hinge-CH2- CH3 domain fused via either a linker or an antibody hinge to an Fab fragment composed of a heavy chain portion comprising a heavy chain variable domain and a heavy chain CH1 domain, and a light chain portion comprising a light chain variable domain and a light chain constant domain
  • the second immunoglobulin heavy chain includes a second Fc (hinge-CH2-CH3) domain fused via either a linker or an antibody hinge to a single-chain variable fragment (scFv) composed of a heavy chain variable domain and light chain variable domain which pair and bind the HER2 antigen.
  • scFv single-chain variable fragment
  • the single-chain variable fragment (scFv) described above is linked to the antibody constant domain via a hinge sequence.
  • the hinge comprises amino acids Ala-Ser. In some other embodiments, the hinge comprises amino acids Ala-Ser and Thr-Lys-Gly. The hinge sequence can provide flexibility of binding to the target antigen, and balance between flexibility and optimal geometry.
  • the single-chain variable fragment (scFv) described above includes a heavy chain variable domain and a light chain variable domain.
  • the heavy chain variable domain forms a disulfide bridge with the light chain variable domain to enhance stability of the scFv.
  • a disulfide bridge can be formed between the C44 residue of the heavy chain variable domain and the C100 residue of the light chain variable domain, the amino acid positions numbered under Kabat.
  • the heavy chain variable domain is linked to the light chain variable domain via a flexible linker. Any suitable linker can be used, for example, the (G4S) 4 linker (SEQ ID NO:203).
  • the heavy chain variable domain is positioned at the N-terminus of the light chain variable domain. In some embodiments of the scFv, the heavy chain variable domain is positioned at the C terminus of the light chain variable domain.
  • the multi- specific binding proteins described herein can further include one or more additional antigen-binding sites.
  • the additional antigen-binding site(s) may be fused to the C-terminus of the constant region CH2 domain or to the C-terminus of the constant region CH3 domain, optionally via a linker sequence.
  • the additional antigen-binding site(s) takes the form of a single-chain variable region (scFv) that is optionally disulfide-stabilized, resulting in a tetravalent or trivalent multi- specific binding protein.
  • a multi-specific binding protein includes an NKG2D-binding site, a HER2-binding site, a third antigen-binding site that binds a tumor-associated antigen, and an antibody constant region or a portion thereof sufficient to bind CD 16, or a fourth antigen binding site that binds CD 16.
  • Any one of these antigen-binding sites can either take the form of an Fab or an scFv, such as the scFv described above.
  • the third antigen-binding site binds a different tumor-associated antigen from HER2.
  • the third antigen-binding site binds to the same tumor-associated antigen HER2, and the exemplary formats are shown in FIGs. 2C and 2D.
  • the multi specific binding proteins can provide bivalent engagement of HER2.
  • Bivalent engagement of HER2 by the multi- specific proteins can stabilize the HER2 on cancer cell surface, and enhance cytotoxicity of NK cells towards the cancer cells.
  • Bivalent engagement of HER2 by the multi- specific proteins can confer stronger binding of the multi- specific proteins to the cancer cells, thereby facilitating stronger cytotoxic response of NK cells towards the cancer cells, especially towards cancer cells expressing a low level of HER2.
  • CD 16 binding is mediated by the hinge region and the CH2 domain.
  • the interaction with CD 16 is primarily focused on amino acid residues Asp 265 - Glu 269, Asn 297 - Thr 299, Ala 327 - Ile 332, Feu 234 - Ser 239, and carbohydrate residue N-acetyl-D-glucosamine in the CH2 domain (see, Sondermann el al., Nature, 406 (6793):267-273).
  • mutations can be selected to enhance or reduce the binding affinity to CD 16, such as by using phage- displayed libraries or yeast surface-displayed cDNA libraries, or can be designed based on the known three-dimensional structure of the interaction.
  • the antibody constant domain comprises a CH2 domain and a CH3 domain of an IgG antibody, for example, a human IgGl antibody.
  • mutations are introduced in the antibody constant domain to enable heterdimerization with another antibody constant domain.
  • the antibody constant domain can comprise an amino acid sequence at least 90% identical to amino acids 234-332 of a human IgGl antibody, and differs at one or more positions selected from the group consisting of Q347, Y349, F351, S354, E356, E357, K360, Q362, S364, T366, F368, K370, N390, K392, T394, D399, S400, D401, F405, Y407, K409, T411, and K439. All the amino acid positions in an Fc domain or hinge region disclosed herein are numbered according to EU numbering.
  • the antibody constant domain can comprise an amino acid sequence at least 90% identical to amino acids 234-332 of a human IgGl antibody, and differs by one or more substitutions selected from the group consisting of Q347E, Q347R, Y349S, Y349K, Y349T, Y349D, Y349E, Y349C, F351K, F351D, F351Y, S354C, E356K, E357Q, E357F, E357W, K360E, K360W, Q362E, S364K, S364E, S364H, S364D, T366V, T366I, T366F, T366M, T366K, T366W, T366S, F368E, F368A, F368D, K370S, N390D, N390E, K392F, K392M, K392V, K
  • Table 1 lists peptide sequences of heavy chain variable domains and light chain variable domains that, in combination, can bind to NKG2D.
  • the heavy chain variable domain and the light chain variable domain are arranged in Fab format.
  • the heavy chain variable domain and the light chain variable domain are fused together to from an scFv.
  • a heavy chain variable domain represented by SEQ ID NO: 1 10 can be paired with a light chain variable domain represented by SEQ ID NO: 11 1 to form an antigen-binding site that can bind to NKG2D, as illustrated in US 9,273, 136.
  • a heavy chain variable domain represented by SEQ ID NO: 1 12 can be paired with a light chain variable domain represented by SEQ ID NO: 113 to form an antigen-binding site that can bind to NKG2D, as illustrated in US 7,879,985.
  • SEQ ID NO: l l2 SEQ ID NO: 1 12
  • the multi-specific binding proteins can bind to NKG2D-expressing cells, which include but are not limited to NK cells, gd T cells and CD8 + ab T cells. Upon NKG2D binding, the multi- specific binding proteins may block natural ligands, such as UFBP6 and MICA, from binding to NKG2D and activating NK cells.
  • NKG2D-expressing cells include but are not limited to NK cells, gd T cells and CD8 + ab T cells.
  • the multi- specific binding proteins may block natural ligands, such as UFBP6 and MICA, from binding to NKG2D and activating NK cells.
  • the multi-specific binding proteins binds to cells expressing CD16, an Fc receptor on the surface of leukocytes including natural killer cells, macrophages, neutrophils, eosinophils, mast cells, and follicular dendritic cells.
  • a protein of the present disclosure binds to NKG2D with an affinity of KD of 2 nM to 120 nM, e.g., 2 nM to 110 nM, 2 nM to 100 nM, 2 nM to 90 nM, 2 nM to 80 nM, 2 nM to 70 nM, 2 nM to 60 nM, 2 nM to 50 nM, 2 nM to 40 nM, 2 nM to 30 nM, 2 nM to 20 nM, 2 nM to 10 nM, about 15 nM, about 14 nM, about 13 nM, about 12 nM, about 11 nM, about 10 nM, about 9 nM, about 8 nM, about 7 nM, about 6 nM, about 5 nM, about 4.5 nM, about 4 nM, about 3.5 nM, about 3 nM, about 2.5 nM, about 2 nM, about 1.5
  • the HER2-binding site of the multi-specific binding protein disclosed herein comprises a heavy chain variable domain and a light chain variable domain fused together to from an scFv.
  • Table 2 lists peptide sequences of heavy chain variable domains and light chain variable domains that, in combination, can bind to HER2.
  • novel antigen-binding sites that can bind to HER2 can be identified by screening for binding to the amino acid sequence defined by SEQ ID NO: 138 or a mature extracellular fragment thereof.
  • KYTMRRLLQETELVEPLTPS GAMPN QAQMRILKETELRKVKVLGS GAFGT V YKGIW
  • DVPV (SEQ ID NO: l38).
  • the VH and VL of the scFv can be positioned in various orientations.
  • the VL is positioned N-terminal to the VH.
  • the VL is positioned C-terminal to the VH.
  • VH and VL of the scFv can be connected via a linker, e.g., a peptide linker.
  • the peptide linker is a flexible linker.
  • peptides are selected with properties that confer flexibility, do not interfere with the structure and function of the other domains of the proteins of the present invention, and resist cleavage from proteases.
  • glycine and serine residues generally provide protease resistance.
  • the VL is positioned N- terminal to the VH and is connected to the VH via a linker.
  • the length of the linker (e.g., flexible linker) can be“short,” e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acid residues, or“long,” e.g., at least 13 amino acid residues.
  • the linker is 10-50, 10-40, 10-30, 10-25, 10-20, 15-50, 15-40, 15-30, 15-25, 15-20, 20-50, 20-40, 20-30, or 20-25 amino acid residues in length.
  • the linker comprises or consists of a (GS) n (SEQ ID NO:204), (GGS) n (SEQ ID NO:205), (GGGS) worship(SEQ ID NO:206), (GGSG) conjunction(SEQ ID NO:207), (GGSGG) n (SEQ ID NO:208), and (GGGGS)connect (SEQ ID NO:209) sequence, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
  • the linker comprises or consists of an amino acid sequence selected from SEQ ID NO: 143, SEQ ID NO:20l, SEQ ID NO:202, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO: 150, SEQ ID NO: 152, and SEQ ID NO: 154, as listed in Table 3.
  • the linker is a (G 4 S) 4 (SEQ ID NO:203) linker consisting of the sequence of SEQ ID NO: 143.
  • CD 16 binding is mediated by the hinge region and the CH2 domain.
  • the interaction with CD 16 is primarily focused on amino acid residues Asp 265 - Glu 269, Asn 297 - Thr 299, Ala 327 - Ile 332, Leu 234 - Ser 239, and carbohydrate residue N-acetyl-D-glucosamine in the CH2 domain (see, Sondermann et al, Nature, 406 (6793):267-273).
  • mutations can be selected to enhance or reduce the binding affinity to CD16, such as by using phage- displayed libraries or yeast surface-displayed cDNA libraries, or can be designed based on the known three-dimensional structure of the interaction.
  • the assembly of heterodimeric antibody heavy chains can be accomplished by expressing two different antibody heavy chain sequences in the same cell, which may lead to the assembly of homodimers of each antibody heavy chain as well as assembly of heterodimers. Promoting the preferential assembly of heterodimers can be accomplished by incorporating different mutations in the CH3 domain of each antibody heavy chain constant region as shown in US 13/494870, US 16/028850, US 11/533709, US 12/875015,
  • mutations can be made in the CH3 domain based on human IgGl and incorporating distinct pairs of amino acid substitutions within a first polypeptide and a second polypeptide that allow these two chains to selectively heterodimerize with each other.
  • the positions of amino acid substitutions illustrated below are all numbered according to the EU index as in Kabat.
  • an amino acid substitution in the first polypeptide replaces the original amino acid with a larger amino acid, selected from arginine (R), phenylalanine (F), tyrosine (Y) or tryptophan (W), and at least one amino acid substitution in the second polypeptide replaces the original amino acid(s) with a smaller amino acid(s), chosen from alanine (A), serine (S), threonine (T), or valine (V), such that the larger amino acid substitution (a protuberance) fits into the surface of the smaller amino acid substitutions (a cavity).
  • one polypeptide can incorporate a T366W substitution, and the other can incorporate three substitutions including T366S, L368A, and Y407V.
  • An antibody heavy chain variable domain of the invention can optionally be coupled to an amino acid sequence at least 90% identical to an antibody constant region, such as an IgG constant region including hinge, CH2 and CH3 domains with or without CH1 domain.
  • the amino acid sequence of the constant region is at least 90% identical to a human antibody constant region, such as a human IgGl constant region, an IgG2 constant region, IgG3 constant region, or IgG4 constant region.
  • the amino acid sequence of the constant region is at least 90% identical to an antibody constant region from another mammal, such as rabbit, dog, cat, mouse, or horse.
  • One or more mutations can be incorporated into the constant region as compared to human IgGl constant region, for example at Q347, Y349, L351, S354, E356, E357, K360, Q362, S364, T366, L368, K370, N390, K392, T394, D399, S400, D401, F405, Y407, K409, T411 and/or K439.
  • Exemplary substitutions include, for example, Q347E, Q347R, Y349S,
  • mutations that can be incorporated into the CH1 of a human IgGl constant region may be at amino acid V125, F126, P127, T135, T139, A140, F170, P171, and/or V173.
  • mutations that can be incorporated into the CK of a human IgGl constant region may be at amino acid E123, Fl 16, S 176, V163,
  • Amino acid substitutions could be selected from the following sets of substitutions shown in Table 4.
  • amino acid substitutions could be selected from the following sets of substitutions shown in Table 5.
  • amino acid substitutions could be selected from the following set of substitutions shown in Table 6.
  • Polypeptide column is replaced by any known negatively-charged amino acid, and the position(s) indicated in the Second Polypeptide Column is replaced by any known positively- charged amino acid.
  • amino acid substitutions could be selected from the following set in
  • the structural stability of a hetero-multimeric protein may be increased by introducing S354C on either of the first or second polypeptide chain, and Y349C on the opposing polypeptide chain, which forms an artificial disulfide bridge within the interface of the two polypeptides.
  • the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region at position T366, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region at one or more positions selected from the group consisting of T366, L368 and Y407.
  • the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region at one or more positions selected from the group consisting of E357, K360, Q362, S364, L368, K370, T394, D401, F405, and T411 and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region at one or more positions selected from the group consisting of Y349, E357, S364, L368, K370, T394, D401, F405 and T411.
  • the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region at one or more positions selected from the group consisting of L351, D399, S400 and Y407 and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region at one or more positions selected from the group consisting of T366, N390, K392, K409 and T411.
  • the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region at one or more positions selected from the group consisting of L351, E356, T366 and D399, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region at one or more positions selected from the group consisting of Y349, L351, L368, K392 and K409.
  • the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region at one or more positions selected from the group consisting of Y349, L351, L368, K392 and K409, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region at one or more positions selected from the group consisting of L351, E356, T366 and D399.
  • the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by an S354C substitution and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by a Y349C substitution.
  • the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by a Y349C substitution and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by an S354C substitution.
  • the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by K360E and K409W substitutions and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by Q347R, D399V and F405T substitutions.
  • the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by Q347R, D399V and F405T substitutions and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by K360E and K409W substitutions.
  • the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by a T366W substitutions and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by T366S, T368A, and Y407V substitutions.
  • the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by T366S, T368A, and Y407V substitutions and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by a T366W substitution.
  • the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by T350V, L351Y, F405A, and Y407V substitutions and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by T350V, T366L, K392L, and T394W substitutions.
  • the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by T350V, T366L, K392L, and T394W substitutions and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgGl constant region by T350V, L351Y, F405A, and Y407V substitutions.
  • the one or more mutations may include E233P; L234A; L235A; N297A, N297Q, N297G, or N297D; and/or P329A, P329G, or P329R relative to wild-type human IgGl.
  • the one or more mutations may include L234A and L235A relative to wild-type human IgGl.
  • the one or more mutations may include L234A, L235A, and P329A relative to wild-type human IgGl.
  • the mutation may be present on each of the two polypeptide chains of the Fc domain.
  • TriNKETs comprising a HER2-binding scFv and an NKG2D-binding Fab each linked to an antibody constant region, wherein the antibody constant regions include mutations that enable heterodimerization of two Fc chains.
  • the scFv comprises a heavy chain variable domain (VH) and a light chain variable domain (VL) derived from an anti-HER2 antibody (e.g., trastuzumab), and further comprises substitution of Cys for the amino acid residues at position 100 of VL and position 44 of VH, thereby facilitating formation of a disulfide bridge between the VH and VL of the scFv.
  • an additional sequence Thr-Lys-Gly can be added N-terminal or C-terminal to the Ala-Ser sequence at the hinge.
  • Fc includes an antibody hinge, CH2, and CH3.
  • each of the TriNKETs described below comprises the following three polypeptide chains:
  • Chain A comprising from N-terminus to C-terminus: VH of an NKG2D-binding Fab, CH1, and Fc;
  • Chain B comprising from N-terminus to C-terminus: VL of a HER2-binding scFv, (G 4 S) 4 linker (SEQ ID NO:203), VH of the HER2-binding scFv, Ala-Ser linker, and Fc; and
  • the multi- specific binding protein of the present disclosure comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first, second, and third polypeptide chains comprise the amino acid sequences of Chain A, Chain B, and Chain C, respectively, of a TriNKET disclosed in Table 11.
  • the first, second, and third polypeptide chains consist of the amino acid sequences of Chain A, Chain B, and Chain C, respectively, of a TriNKET disclosed in Table 11.
  • the scFv (SEQ ID NO: 139) includes a heavy chain variable domain of trastuzumab connected to the N-terminus of a light chain variable domain of trastuzumab via a (G 4 S) 4 linker (SEQ ID NO:203), the scFv represented as VL-(G 4 S) 4 -VH (“(G 4 S) 4 ” is represented by SEQ ID NO:203 or SEQ ID NO: 143).
  • the heavy and the light variable domains of the scFv are also connected through a disulfide bridge between Cl 00 of VL and C44 of VH, as a result of Q100C and G44C substitutions in the VL and VH, respectively.
  • SEQ ID NO: 140 represents the heavy chain portion of the Fab fragment, which comprises a heavy chain variable domain (SEQ ID NO:94) of an NKG2D-binding site and a CH1 domain, connected to an Fc domain.
  • the Fc domain in SEQ ID NO: 141 includes a Y349C substitution in the CH3 domain, which forms a disulfide bond with an S354C substitution on the Fc linked to the HER2-binding scFv (SEQ ID NO: 140).
  • the Fc domain also includes K360E and K409W substitutions for heterodimerization with the Fc in SEQ ID NO: 140.
  • SEQ ID NO: 142 represents the light chain portion of the Fab fragment comprising a light chain variable domain (SEQ ID NO:98) of an NKG2D-binding site and a light chain constant domain.
  • A49MI-F3’-TriNKET- Trastuzumab includes the same Her2 -binding scFv (SEQ ID NO: 139) as in A49-F3’-TriNKET-Trastuzumab linked via a hinge comprising Ala- Ser to an Fc domain; and an NKG2D-binding Fab fragment derived from A49MI including a heavy chain portion comprising a heavy chain variable domain (SEQ ID NO: 144) and a CH1 domain, and a light chain portion comprising a light chain variable domain (SEQ ID NO:98) and a light chain constant domain, wherein the heavy chain variable domain is connected to the CH1 domain, and the CH1 domain is connected to the Fc domain.
  • A49MI-F3’-TriNKET- Trastuzumab includes three polypeptides, having the sequences of SEQ ID NO: 140 (as in A49-F3’ -TriNKET -Trastuzumab), SEQ ID NO: l45, and SEQ ID NO: l42 (as in A49-F3’- T riNKET -T rastuzumab) .
  • SEQ ID NO: 145 represents a heavy chain portion of the Fab fragment, which comprises a heavy chain variable domain (SEQ ID NO: 144) of an NKG2D-binding site and a CH1 domain, connected to an Fc domain.
  • SEQ ID NO: 144 wherein a methionine in the CDR3 of SEQ ID NO:94 has been substituted by isoleucine (M -> I substitution; shown within a third bracket [] in SEQ ID NO: 144 and SEQ ID NO: 145).
  • the Fc domain in SEQ ID NO: 145 includes a Y349C substitution in the CH3 domain, which forms a disulfide bond with an S354C substitution in the Fc linked to the HER2-binding scFv (SEQ ID NO: 140).
  • the Fc domain also includes K360E and K409W substitutions.
  • KiH refers to the knobs-into-holes (KiH) Fc technology, which involves engineering of the CH3 domains to create either a“knob” or a“hole” in each heavy chain to promote heterodimerization.
  • KiH Fc technology was to introduce a “knob” in one CH3 domain (CH3A) by substitution of a small residue with a bulky one (e.g . , T366W CH3 A in EU numbering).
  • a complementary“hole” surface was created on the other CH3 domain (CH3B) by replacing the closest neighboring residues to the knob with smaller ones (e.g., T366S/L368A/Y407V CH3B ).
  • The“hole” mutation was optimized by structured-guided phage library screening (Atwell S, Ridgway JB, Wells JA, Carter P., Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library, J. Mol. Biol. (1997) 270(l):26-35).
  • KiH Fc variants X-ray crystal structures of KiH Fc variants (Elliott JM, Ultsch M, Lee J, Tong R, Takeda K, Spiess C, et al, Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction. J. Mol. Biol. (2014) 426(9): 1947-57;
  • A49-F3’-KiH-TriNKET-Trastuzumab includes the same Her2-binding scFv (SEQ ID NO: 139) as in A49-F3’-TriNKET-Trastuzumab linked via a hinge comprising Ala-Ser to an Fc domain comprising the“hole” substitutions of T366S, L368A, and Y407V; and the same NKG2D-binding Fab fragment as in A49-F3’-TriNKET-Trastuzumab, the CH1 domain of which is connected to an Fc domain comprising the“knob” substitution of T366W.
  • A49- F3’-KiH-TriNKET-Trastuzumab includes three polypeptides, having the sequences of SEQ ID NO: 146, SEQ ID NO: 147, and SEQ ID NO: 142 (as in A49-F3’-TriNKET-Trastuzumab).
  • SEQ ID NO: 146 represents the full sequence of the HER2-binding scFv (SEQ ID NO: 139) linked to an Fc domain via a hinge comprising Ala-Ser (scFv-Fc).
  • the Fc domain linked to the scFv includes T366S, L368A, and Y407V substitutions for heterodimerization and an S354C substitution for forming a disulfide bond with a Y349C substitution in SEQ ID NO: 147 as described below.
  • the Fc domain also includes a T366W substitution.
  • A49MI-F3’-KiH-TriNKET- Trastuzumab is A49MI-F3’-KiH-TriNKET- Trastuzumab.
  • A49MI-F3’-KiH-TriNKET-Trastuzumab includes the same Her2-binding scFv (SEQ ID NO: 139) as in A49-F3’-TriNKET-Trastuzumab linked via a hinge comprising Ala- Ser to an Fc domain comprising the“hole” substitutions of T366S, L368A, and Y407V; and the same NKG2D-binding Fab fragment as in A49MI-F3’-TriNKET-Trastuzumab, the CH1 domain of which is connected to an Fc domain comprising the“knob” substitution of T366W.
  • A49MI-F3’-KiH-TriNKET-Trastuzumab includes three polypeptides, having the sequences of SEQ ID NO: 146 (as in A49-F3’-KiH-TriNKET-Trastuzumab), SEQ ID NO: 146 (as in A49-F3’-KiH-TriNKET-Trastuzumab), SEQ ID NO: 146 (as in A49-F3’-KiH-TriNKET-Trastuzumab), SEQ ID NO: 146 (as in A49-F3’-KiH-TriNKET-Trastuzumab), SEQ ID NO: 146 (as in A49-F3’-KiH-TriNKET-Trastuzumab), SEQ ID NO: 146 (as in A49-F3’-KiH-TriNKET-Trastuzumab), SEQ ID NO: 146 (as in A49-F
  • SEQ ID NO: 194 represents the heavy chain portion of a Fab fragment, which comprises a heavy chain variable domain (SEQ ID NO: 144) of an NKG2D-binding site derived from A49MI and a CH1 domain, connected to an Fc domain.
  • the Fc domain in SEQ ID NO: 194 includes an S354C substitution, which forms a disulfide bond with a Y349C substitution in the CH3 domain of the Fc linked to the HER2-binding scFv (SEQ ID NO: 144) of an NKG2D-binding site derived from A49MI and a CH1 domain, connected to an Fc domain.
  • the Fc domain in SEQ ID NO: 194 includes an S354C substitution, which forms a disulfide bond with a Y349C substitution in the CH3 domain of the Fc linked to the HER2-binding scFv (SEQ ID NO: 144) of an NKG2D-binding site derived from A49MI and a
  • the Fc domain also includes a T366W substitution.
  • TriNKET of the present disclosure is A44-F3’ -TriNKET -
  • A44-F3’-TriNKET-Trastuzumab includes the same Her2-binding scFv (SEQ ID NO: 139) as in A49-F3’-TriNKET-Trastuzumab linked via a hinge comprising Ala-Ser to an Fc domain; and an NKG2D-binding Fab fragment derived from A44 including a heavy chain portion comprising a heavy chain variable domain (SEQ ID NO:86) and a CH1 domain, and a light chain portion comprising a light chain variable domain (SEQ ID NO:90) and a light chain constant domain, wherein the heavy chain variable domain is connected to the CH1 domain, and the CH1 domain is connected to the Fc domain.
  • A44-F3’-TriNKET- Trastuzumab includes three polypeptides, having the sequences of SEQ ID NO: 140 (as in A49-F3’ -TriNKET -Trastuzumab), SEQ ID NO: 155, and SEQ ID NO: 149.
  • SEQ ID NO: 155 represents a heavy chain variable domain (SEQ ID NO:86) of an NKG2D-binding site derived from A44, connected to an Fc domain.
  • the Fc domain in SEQ ID NO: 155 includes a Y349C substitution in the CH3 domain, which forms a disulfide bond with an S354C substitution on the Fc linked to the HER2-binding scFv (SEQ ID NO: 140).
  • the Fc domain also includes K360E and K409W substitutions.
  • A44-F3’-KiH-TriNKET-Trastuzumab includes the same Her2- binding scFv (SEQ ID NO: 139) as in A49-F3’-TriNKET-Trastuzumab linked via a hinge comprising Ala-Ser to an Fc domain comprising the“hole” substitutions of T366S, L368A, and Y407V; and the same NKG2D-binding Fab fragment as in A44-F3’ -TriNKET - Trastuzumab, the CH1 domain of which is connected to an Fc domain comprising the“knob” substitution of T366W.
  • A44-F3’-KiH-TriNKET-Trastuzumab includes three polypeptides, having the sequences of SEQ ID NO: 146 (as in A49-F3’-KiH-TriNKET-Trastuzumab), SEQ ID NO: 148, and SEQ ID NO: 149 (as in A44-F3’-TriNKET-Trastuzumab).
  • SEQ ID NO: 148 represents a heavy chain variable domain (SEQ ID NO:86) of an NKG2D-binding site derived from A44, connected to an Fc domain.
  • the Fc domain in SEQ ID NO: 148 includes a Y349C substitution in the CH3 domain, which forms a disulfide bond with an S354C substitution on the Fc linked to the HER2-binding scFv (SEQ ID NO: 146).
  • the Fc domain also includes a T366W substitution.
  • pertuzumab that binds HER2, linked via a hinge comprising Ala-Ser to an Fc domain; and and the same NKG2D-binding Fab fragment as in A49-F3’-TriNKET-Trastuzumab, the CH1 domain of which is connected to an Fc domain.
  • the Fc domain linked to the scFv includes Q347R, D399V, and F405T substitutions
  • the Fc domain linked to the Fab fragment includes K360E and K409W substitutions.
  • the scFv (SEQ ID NO: 189) includes a heavy chain variable domain of pertuzumab connected to the N-terminus of a light chain variable domain of pertuzumab via a (G 4 S) 4 linker (SEQ ID NO:203), the scFv represented as VL-(G 4 S) 4 -VH (“(G 4 S) 4 ” is represented by SEQ ID NO:203 or SEQ ID NO: 143).
  • the heavy and the light variable domains of the scFv are also connected through a disulfide bridge between C100 of VL and C44 of VH, as a result of Q100C and G44C substitutions in the VL and VH, respectively.
  • TriNKET (SEQ ID NO: 190)
  • Another exemplary TriNKET of the present disclosure is A49MI-F3’-TriNKET-
  • A49-F3’-KiH-TriNKET-Pertuzumab includes three polypeptides, having the sequences of SEQ ID NO: l9l, SEQ ID NO: l47 (as in A49-F3’-KiH-TriNKET-Trastuzumab), and SEQ ID NO: 142 (as in A49-F3’-TriNKET-Trastuzumab).
  • SEQ ID NO: 191 represents the full sequence of the HER2-binding scFv (SEQ ID NO: 191
  • the Fc domain linked to the scFv includes the“hole” substitutions of T366S, L368A, and Y407V
  • the Fc domain linked to the Fab fragment includes the“knob” substitution of T366W.
  • A49MI-F3’-KiH-TriNKET-Pertuzumab includes three polypeptides, having the sequences of SEQ ID NO: 191 (as in A49-F3’-KiH-TriNKET-Pertuzumab), SEQ ID NO: 194 (as in A49MI-F3’ -KiH-TriNKET -Trastuzumab), and SEQ ID NO: 142 (as in A49-F3’- TriNKET -Trastuzumab) .
  • A44-F3’ -TriNKET - Pertuzumab Another exemplary TriNKET of the present disclosure is A44-F3’ -TriNKET - Pertuzumab.
  • A44-F3’-TriNKET-Pertuzumab includes the same Her2-binding scFv (SEQ ID NO: 189) as in A49-F3’-TriNKET-Pertuzumab linked via a hinge comprising Ala-Ser to an Fc domain; and the same NKG2D-binding Fab fragment as in A44-F3’ -TriNKET- Trastuzumab, the CH1 domain of which is connected to an Fc domain.
  • the Fc domain linked to the scFv includes the“hole” substitutions of T366S, L368A, and Y407V
  • the Fc domain linked to the Fab fragment includes the“knob” substitution of T366W.
  • A44-F3’-KiH-TriNKET-Pertuzumab includes three polypeptides, having the sequences of SEQ ID NO: 191 (as in A49-F3’-KiH-TriNKET-Pertuzumab), SEQ ID NO: 148 (as in A44- F3’ -KiH-TriNKET -Trastuzumab), and SEQ ID NO: 149 (as in A44-F3’ -TriNKET- Trastuzumab).
  • SEQ ID NO: 192 represents the full sequence of the HER2-binding scFv linked to an Fc domain via a hinge comprising Ala-Ser (scFv-Fc).
  • the Fc domain linked to the scFv includes Q347R, D399V, and F405T substitutions for heterodimerization and an S354C substitution for forming a disulfide bond with a Y349C substitution in SEQ ID NO: 141 as described above.
  • TriNKET of the present disclosure is A49MI-F3’ -TriNKET-MGAH22.
  • A49MI-F3’ -TriNKET -MGAH22 includes the same Her2-binding scFv (SEQ ID NO: l7 l) as in A49-F3’-TriNKET-MGAH22 linked via a hinge comprising Ala-Ser to an Fc domain; and the same NKG2D-binding Fab fragment as in A49MI-F3’-TriNKET-Trastuzumab, the CH1 domain of which is connected to an Fc domain.
  • the Fc domain linked to the scFv includes Q347R, D399V, and F405T substitutions, and the Fc domain linked to the Fab fragment includes K360E and K409W substitutions.
  • A49MI-F3’ -KiH-TriNKET-MGAH22 includes three polypeptides, having the sequences of SEQ ID NO: 192 (as in A49-F3’ -TriNKET - MGAH22), SEQ ID NO: 145 (as in A49MI-F3’-TriNKET-Trastuzumab), and SEQ ID NO: 142 (as in A49-F3’-TriNKET-Trastuzumab).
  • A49-F3’-KiH-TriNKET- MGAH22 is A49-F3’-KiH-TriNKET- MGAH22.
  • A49-F3’ -KiH-TriNKET -MGAH22 includes the same Her2-binding scFv (SEQ ID NO: l7 l) as in A49-F3’-TriNKET-MGAH22 linked via a hinge comprising Ala-Ser to an Fc domain; and the same NKG2D-binding Fab fragment as in A49-F3’ -TriNKET - Trastuzumab, the CH1 domain of which is connected to an Fc domain.
  • the Fc domain linked to the scFv includes the“hole” substitutions of T366S, L368A, and Y407V
  • the Fc domain linked to the Fab fragment includes the“knob” substitution of T366W.
  • A49-F3’- KiH-TriNKET-MGAH22 includes three polypeptides, having the sequences of SEQ ID NO: 193, SEQ ID NO: 147 (as in A49-F3’ -KiH-TriNKET -Trastuzumab), and SEQ ID NO: 142 (as in A49-F3’-TriNKET-Trastuzumab).
  • SEQ ID NO: 193 represents the full sequence of the HER2-binding scFv (SEQ ID NO: 171) linked to an Fc domain via a hinge comprising Ala-Ser (scFv-Fc).
  • the Fc domain linked to the scFv includes T366S, L368A, and Y407V substitutions for heterodimerization and an S354C substitution for forming a disulfide bond with a Y349C substitution in SEQ ID NO: 147 as described above.
  • TriNKET of the present disclosure is A49MI-F3’-KiH-
  • A49MI-F3’ -KiH-TriNKET -MGAH22 includes the same Her2-binding scFv (SEQ ID NO: l7 l) as in A49-F3’-TriNKET-MGAH22 linked via a hinge comprising Ala-Ser to an Fc domain; and the same NKG2D-binding Fab fragment as in A49MI-F3’- TriNKET-Trastuzumab, the CH1 domain of which is connected to an Fc domain.
  • the Fc domain linked to the scFv includes the“hole” substitutions of T366S, L368A, and Y407V
  • the Fc domain linked to the Fab fragment includes the“knob” substitution of T366W.
  • A49MI-F3’-KiH-TriNKET-MGAH22 includes three polypeptides, having the sequences of SEQ ID NO: 193 (as in A49-F3’ -KiH-TriNKET-MGAH22), SEQ ID NO: 194 (as in A49MI- F3’ -KiH-TriNKET -Trastuzumab), and SEQ ID NO: 142 (as in A49-F3’ -TriNKET - Trastuzumab).
  • A44-F3’ -TriNKET -MGAH22 includes the same Her2-binding scFv (SEQ ID NO:l7l) as in A49-F3’-TriNKET-MGAH22 linked via a hinge comprising Ala-Ser to an Fc domain; and the same NKG2D-binding Fab fragment as in A44-F3’-TriNKET-Trastuzumab, the CH1 domain of which is connected to an Fc domain.
  • the Fc domain linked to the scFv includes Q347R, D399V, and F405T substitutions, and the Fc domain linked to the Fab fragment includes K360E and K409W substitutions.
  • A44-F3’-TriNKET-MGAH22 includes three polypeptides, having the sequences of SEQ ID NO: 192 (as in A49-F3’ -TriNKET - MGAH22), SEQ ID NO: 155 (as in A44-F3’-TriNKET-Trastuzumab), and SEQ ID NO: 149 (as in A44-F3’-TriNKET-Trastuzumab).
  • A44-F3’-KiH- TriNKET-MGAH22 is A44-F3’-KiH- TriNKET-MGAH22.
  • A44-F3’ -KiH-TriNKET -MGAH22 includes the same Her2-binding scFv (SEQ ID NO:l7l) as in A49-F3’-TriNKET-MGAH22 linked via a hinge comprising Ala-Ser to an Fc domain; and the same NKG2D-binding Fab fragment as in A44-F3’- TriNKET-Trastuzumab, the CH1 domain of which is connected to an Fc domain.
  • the Fc domain linked to the scFv includes the“hole” substitutions of T366S, L368A, and Y407V
  • the Fc domain linked to the Fab fragment includes the“knob” substitution of T366W.
  • A44-F3’-KiH-TriNKET-MGAH22 includes three polypeptides, having the sequences of SEQ ID NO:l93 (as in A49-F3’-KiH-TriNKET-MGAH22), SEQ ID NO:l48 (as in A44-F3’-KiH- TriNKET-Trastuzumab), and SEQ ID NO: 149 (as in A44-F3’ -TriNKET- Trastuzumab).
  • a TriNKET of the present disclosure is identical to one of the exemplary TriNKETs described above that includes the EW-RVT Fc mutations, except that the Fc domain linked to the NKG2D-binding Fab fragment comprises the substitutions of Q347R, D399V, and F405T, and the Fc domain linked to the HER2-binding scFv comprises matching substitutions K360E and K409W for forming a heterodimer.
  • a TriNKET of the present disclosure is identical to one of the exemplary TriNKETs described above that includes the KiH Fc mutations, except that the Fc domain linked to the NKG2D-binding Fab fragment comprises the“hole” substitutions of T366S, L368A, and Y407V, and the Fc domain linked to the HER2-binding scFv comprises the “knob” substitution of T366W for forming a heterodimer.
  • a TriNKET of the present disclosure is identical to one of the exemplary TriNKETs described above, except that the Fc domain linked to the NKG2D- binding Fab fragment includes an S354C substitution in the CH3 domain, and the Fc domain linked to the HER2-binding scFv includes a matching Y349C substitution in the CH3 domain for forming a disulfide bond.
  • N-terminal glutamate (E) or glutamine (Q) can be cyclized to form a lactam (e.g., spontaneously or catalyzed by an enzyme present during production and/or storage).
  • N-terminal residue of an amino acid sequence of a polypeptide is E or Q
  • a corresponding amino acid sequence with the E or Q replaced with pyroglutamate is also contemplated herein.
  • the C-terminal lysine (K) of a protein can be removed (e.g., spontaneously or catalyzed by an enzyme present during production and/or storage). Such removal of K is often observed with proteins that comprise an Fc domain at its C-terminus. Accordingly, in some embodiments where the C-terminal residue of an amino acid sequence of a polypeptide (e.g., an Fc domain sequence) is K, a corresponding amino acid sequence with the K removed is also contemplated herein.
  • the multi- specific proteins described above can be made using recombinant DNA technology well known to a skilled person in the art.
  • a first nucleic acid sequence encoding the first immunoglobulin heavy chain can be cloned into a first expression vector
  • a second nucleic acid sequence encoding the second immunoglobulin heavy chain can be cloned into a second expression vector
  • a third nucleic acid sequence encoding the immunoglobulin light chain can be cloned into a third expression vector
  • the first, second, and third expression vectors can be stably transfected together into host cells to produce the multimeric proteins.
  • the multi- specific proteins can be isolated and purified using methods known in the art including centrifugation, depth filtration, cell lysis, homogenization, freeze-thawing, affinity purification, gel filtration, ion exchange chromatography, hydrophobic interaction exchange chromatography, and mixed mode chromatography.
  • a multi-specific binding protein of the present disclosure e.g., A49-F3’-TriNKET-Trastuzumab, which include an NKG2D-binding Fab fragment and a HER2-binding scFv domain, bind to cells expressing low levels of HER2 at a level higher than a monoclonal antibody having the same HER2-binding domain.
  • the multi specific binding proteins that include an NKG2D-binding Fab domain and a HER2-binding svFv domain derived from trastuzumab, e.g., A49-F3’-TriNKET-Trastuzumab, can bind to low-HER2 expressing cells at a level higher than trastuzumab.
  • the multi-specific binding proteins described herein are more effective in reducing tumor growth and killing cancer cells.
  • a multi- specific binding protein of the present disclosure that targets HER2-expressing tumor/cancer cells is more effective than trastuzumab.
  • a TriNKET of the present disclosure A49-F3’ -TriNKET - Trastuzumab (comprising an HER2-binding scFv (SEQ ID NO: 139) linked to an Fc domain via a hinge comprising Ala-Ser (scFv-Fc represented by SEQ ID NO: 140); and an NKG2D- binding Fab fragment including a heavy chain portion comprising a heavy chain variable domain of ADI-27749 (A49) (SEQ ID NO:94) and a CH1 domain, and a light chain portion comprising a light chain variable domain (SEQ ID NO:98) and a light chain constant domain, where the heavy chain variable domain is connected to the CH1, and the CH1 domain is connected to the Fc domain (heavy chain portion represented as VH-CHl-Fc, amino acid sequence set forth in SEQ ID NO: 141)) is effective in promoting NK-mediated cell lysis of a human cancer cell line with low level of HER2 expression (HER2+), while
  • A49-F3’ -TriNKET -Trastuzumab has superior NK-mediated cell lysis of a human cancer cell line with higher expression than the HER2+ cell line (HER2++) compared to trastuzumab. And even against a human cancer cell line with the highest level of HER2 expression (compared to HER+ and HER2++ cell lines) (HER2+++), A49-F3’ -TriNKET -Trastuzumab has superior NK-mediated cell lysis compared to trastuzumab.
  • the multi-specific binding proteins described herein including an NKG2D-binding domain e.g., A49-F3’-TriNKET-Trastuzumab, A49MI-F3’- TriNKET-Trastuzumab, A49-F3’ -KiH-TriNKET-Trastuzumab, A44-F3’ -TriNKET- Trastuzumab
  • an NKG2D-binding domain e.g., A49-F3’-TriNKET-Trastuzumab, A49MI-F3’- TriNKET-Trastuzumab, A49-F3’ -KiH-TriNKET-Trastuzumab, A44-F3’ -TriNKET- Trastuzumab
  • the multi specific binding proteins including an NKG2D-binding domain are more effective against cancer metastases than monoclonal antibodies that include the same tumor antigen-binding domain.
  • the multi-specific binding proteins described herein including an NKG2D- binding domain e.g., A49-F3’-TriNKET-Trastuzumab, A49MI-F3’-TriNKET-Trastuzumab, A49-F3’ -KiH-TriNKET-Trastuzumab, A44-F3’-TriNKET-Trastuzumab
  • NKG2D-binds to bind to non- cancerous human cells e.g., human cardiomyocytes
  • HER2++ cancer cells (medium level expression).
  • the multi-specific binding proteins do not induce NK-mediated killing of healthy non- cancerous human cells (e.g., human cardiomyocytes).
  • the multi-specific binding proteins described herein including an NKG2D- binding domain e.g., A49-F3’-TriNKET-Trastuzumab, A49MI-F3’-TriNKET-Trastuzumab, A49-F3’ -KiH-TriNKET-Trastuzumab, A44-F3’-TriNKET-Trastuzumab
  • TAA+ Tumor-Associated Antigen positive
  • A49-F3’- TriNKET-Trastuzumab enhances the cytotoxic activity of human primary CD8+ T cells after culture with IL-15 in a dose-dependent manner (FIG. 13A).
  • A49-F3’ -TriNKET -Trastuzumab also enhances the cytotoxic activity of human primary CD8+ T cells after culture with IL-2 (FIG. 13B).
  • anti-HER2 monoclonal antibodies margetuximab or trastuzumab does not have similar effects.
  • Margetuximab (also called MGAH22) is an Fc-optimized monoclonal antibody that binds HER2.
  • the heavy chain variable domain of margetuximab is represented by SEQ ID NO: 130
  • the light chain variable domain of margetuximab is represented by SEQ ID NO: 134.
  • Margetuximab includes F243L, R292P, Y300L, and P396L substitutions in the Fc domain, which are designed to be ADCC enhancing mutations.
  • the heavy chain and light chain sequences are provided in SEQ ID NO: 151 and SEQ ID NO: 153, respectively.
  • the F243L, R292P, Y300L, and P396L substitutions are bold-underlined.
  • A49-F3’-TriNKET-Trastuzumab shows weak binding to cells expressing NKG2D.
  • the multi- specific binding proteins described herein including an NKG2D-binding domain exhibit a significant advantage in potency and maximum lysis of target cells compared to the combination of Fc-silent TriNKET (“A49si-F3’-TriNKET-Trastuzumab”; the amino acid sequence of the constant region has L234A, L235A, and P329G (LALAPG) mutations, which reduce effector functions of the Fc), and trastuzumab, when the target cells were HER2+ (786-0 cells) (FIG. 19) or HER2++ (H661 cells) (FIG. 20), suggesting A49- F3’ -TriNKET -Trastuzumab can media
  • the multi-specific binding proteins described herein are advantageous in treating HER2-expressing cancers.
  • the invention provides methods for treating cancer using a multi- specific binding protein described herein and/or a pharmaceutical composition described herein.
  • the methods may be used to treat a variety of cancers which express HER2 by administering to a patient in need thereof a therapeutically effective amount of a multi- specific binding protein described herein.
  • the therapeutic method can be characterized according to the cancer to be treated.
  • the cancer is breast, ovarian, esophageal, bladder or gastric cancer, salivary duct carcinoma, salivary duct carcinomas, adenocarcinoma of the lung or aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma.
  • the cancer is brain cancer, breast cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, leukemia, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, or uterine cancer.
  • the cancer is a squamous cell carcinoma, adenocarcinoma, small cell carcinoma, melanoma, neuroblastoma, sarcoma (e.g., an angiosarcoma or chondrosarcoma), larynx cancer, parotid cancer, bilary tract cancer, thyroid cancer, acral lentiginous melanoma, actinic keratoses, acute lymphocytic leukemia, acute myeloid leukemia, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, anal canal cancer, anal cancer, anorectum cancer, astrocytic tumor, bartholin gland carcinoma, basal cell carcinoma, biliary cancer, bone cancer, bone marrow cancer, bronchial cancer, bronchial gland carcinoma, carcinoid, cholangiocarcinoma, chondo sarcoma, chori
  • endometrioid adenocarcinoma endothelial cell cancer, ependymal cancer, epithelial cell cancer, Ewing's sarcoma, eye and orbit cancer, female genital cancer, focal nodular hyperplasia, gallbladder cancer, gastric antrum cancer, gastric fundus cancer, gastrinoma, glioblastoma, glucagonoma, heart cancer, hemangiblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatobiliary cancer, hepatocellular carcinoma, Hodgkin's disease, ileum cancer, insulinoma, intaepithelial neoplasia,
  • interepithelial squamous cell neoplasia intrahepatic bile duct cancer, invasive squamous cell carcinoma, jejunum cancer, joint cancer, Kaposi's sarcoma, pelvic cancer, large cell carcinoma, large intestine cancer, leiomyosarcoma, lentigo maligna melanomas, lymphoma, male genital cancer, malignant melanoma, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, meningeal cancer, mesothelial cancer, metastatic carcinoma, mouth cancer, mucoepidermoid carcinoma, multiple myeloma, muscle cancer, nasal tract cancer, nervous system cancer, neuroepithelial adenocarcinoma nodular melanoma, non-epithelial skin cancer, non-Hodgkin's lymphoma, oat cell carcinoma, oligodendroglial cancer, oral cavity cancer,
  • the cancer is non-Hodgkin’s lymphoma, such as a B-cell lymphoma or a T-cell lymphoma.
  • the non-Hodgkin’s lymphoma is a B-cell lymphoma, such as a diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone B-cell lymphoma, extranodal marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, or primary central nervous system (CNS) lymphoma.
  • B-cell lymphoma such as a diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphom
  • the non-Hodgkin’s lymphoma is a T-cell lymphoma, such as a precursor T-lymphoblastic lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, angioimmunoblastic T-cell lymphoma, extranodal natural killer/T-cell lymphoma, enteropathy type T-cell lymphoma, subcutaneous
  • panniculitis-like T-cell lymphoma panniculitis-like T-cell lymphoma, anaplastic large cell lymphoma, or peripheral T-cell lymphoma.
  • the cancer is breast cancer, thyroid cancer, gastric cancer, renal cell carcinoma, adenocarcinoma of the lung, prostate cancer,
  • cholangiocarcinoma uterine cancer, pancreatic cancer, colorectal cancer, ovarian cancer, cervical cancer, head and neck cancer, lung squamous, mesothelioma, liver cancer, sarcoma, and gall bladder cancer.
  • the cancer to be treated can be characterized according to the presence of a particular antigen expressed on the surface of the cancer cell.
  • the cancer cell can express one or more of the following in addition to HER2: CD2, CD 19, CD20, CD30, CD38, CD40, CD52, CD70, EGFR/ERBB1, IGF1R, HER3/ERBB3,
  • HER4/ERBB4 MUC1, cMET, SLAMF7, PSCA, MICA, MICB, TRAILR1, TRAILR2, MAGE- A3, B7.1, B7.2, CTLA4, and PD1.
  • a multi specific binding protein described herein can be used in combination with additional therapeutic agents to treat cancer.
  • Exemplary therapeutic agents that may be used as part of a combination therapy in treating cancer, include, for example, radiation, mitomycin, tretinoin, ribomustin,
  • gemcitabine vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine, bicalutamide, vinorelbine, vesnarinone, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, isotretinoin, streptozocin, nimustine, vindesine, flutamide, drogenil, butocin, carmofur, razoxane, sizofilan
  • agents that may be used as part of a combination therapy in treating cancer are monoclonal antibody agents that target non-checkpoint targets (e.g ., herceptin) and non-cytotoxic agents (e.g., tyrosine-kinase inhibitors).
  • non-checkpoint targets e.g ., herceptin
  • non-cytotoxic agents e.g., tyrosine-kinase inhibitors
  • Proteins of the invention can also be used as an adjunct to surgical removal of the primary lesion.
  • freeze dried formulation from 12, 27, or 45 vials are combined to obtained a therapeutic dose of the protein in the intravenous drug formulation.
  • the formulation may be a liquid formulation and stored as about 250 mg/vial to about 1000 mg/vial. In certain embodiments, the formulation may be a liquid formulation and stored as about 600 mg/vial. In certain embodiments, the formulation may be a liquid formulation and stored as about 250 mg/vial.
  • the protein could exist in a liquid aqueous pharmaceutical formulation including a therapeutically effective amount of the protein in a buffered solution forming a formulation.
  • the present disclosure provides a formulation with an extended shelf life including the protein of the present disclosure, in combination with mannitol, citric acid monohydrate, sodium citrate, disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, polysorbate 80, water, and sodium hydroxide.
  • the buffer system includes about 1.3 mg/mL of citric acid (e.g., 1.305 mg/mL), about 0.3 mg/mL of sodium citrate (e.g., 0.305 mg/mL), about 1.5 mg/mL of disodium phosphate dihydrate (e.g., 1.53 mg/mL), about 0.9 mg/mL of sodium dihydrogen phosphate dihydrate (e.g., 0.86), and about 6.2 mg/mL of sodium chloride (e.g., 6.165 mg/mL).
  • citric acid e.g., 1.305 mg/mL
  • sodium citrate e.g. 0.305 mg/mL
  • 1.5 mg/mL of disodium phosphate dihydrate e.g., 1.53 mg/mL
  • about 0.9 mg/mL of sodium dihydrogen phosphate dihydrate e.g., 0.86
  • sodium chloride e.g., 6.165 mg/mL
  • the formulation may contain between about 0.1 mg/mL and about 10 mg/mL of polysorbate 80, or between about 0.5 mg/mL and about 5 mg/mL. In certain embodiments, about 0.1% polysorbate 80 may be added in the formulation.
  • the sugar may be disaccharides, e.g., sucrose.
  • the liquid formulation may also include one or more of a buffering agent, a surfactant, and a preservative.
  • the pH of the liquid formulation may be set by addition of a pharmaceutically acceptable acid and/or base.
  • the pH of the liquid formulation may be set by addition of a pharmaceutically acceptable acid and/or base.
  • pharmaceutically acceptable acid may be hydrochloric acid.
  • the base may be sodium hydroxide.
  • deamidation is a common product variant of peptides and proteins that may occur during fermentation, harvest/cell clarification, purification, drug substance/drug product storage and during sample analysis.
  • Deamidation is the loss of NH 3 from a protein forming a succinimide intermediate that can undergo hydrolysis.
  • the succinimide intermediate results in a 17 dalton mass decrease of the parent peptide.
  • the subsequent hydrolysis results in an 18 dalton mass increase.
  • Isolation of the succinimide intermediate is difficult due to instability under aqueous conditions. As such, deamidation is typically detectable as 1 dalton mass increase. Deamidation of an asparagine results in either aspartic or isoaspartic acid.
  • the parameters affecting the rate of deamidation include pH, temperature, solvent dielectric constant, ionic strength, primary sequence, local polypeptide conformation and tertiary structure.
  • the amino acid residues adjacent to Asn in the peptide chain affect deamidation rates. Gly and Ser following an Asn in protein sequences results in a higher susceptibility to deamidation.
  • the liquid formulation of the present disclosure may be preserved under conditions of pH and humidity to prevent deamination of the protein product.
  • the aqueous carrier of interest herein is one which is pharmaceutically acceptable (safe and non-toxic for administration to a human) and is useful for the preparation of a liquid formulation.
  • Illustrative carriers include sterile water for injection (SWFI), bacteriostatic water for injection (BWFI), a pH buffered solution (e.g ., phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution.
  • a preservative may be optionally added to the formulations herein to reduce bacterial action.
  • the addition of a preservative may, for example, facilitate the production of a multi-use (multiple-dose) formulation.
  • IV formulations may be the preferred administration route in particular instances, such as when a patient is in the hospital after transplantation receiving all drugs via the IV route.
  • the liquid formulation is diluted with 0.9% Sodium Chloride solution before administration.
  • the diluted drug product for injection is isotonic and suitable for administration by intravenous infusion.
  • a salt or buffer components may be added in an amount of about 10 mM to 200 mM.
  • the salts and/or buffers are pharmaceutically acceptable and are derived from various known acids (inorganic and organic) with“base forming” metals or amines.
  • the buffer may be phosphate buffer.
  • the buffer may be glycinate, carbonate, citrate buffers, in which case, sodium, potassium or ammonium ions can serve as counterion.
  • a preservative may be optionally added to the formulations herein to reduce bacterial action.
  • the addition of a preservative may, for example, facilitate the production of a multi-use (multiple-dose) formulation.
  • the aqueous carrier of interest herein is one which is pharmaceutically acceptable (safe and non-toxic for administration to a human) and is useful for the preparation of a liquid formulation.
  • Illustrative carriers include sterile water for injection (SWFI), bacteriostatic water for injection (BWFI), a pH buffered solution (e.g., phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution.
  • the lyoprotectant may be sucrose or maltose.
  • the lyophilized formulation may also include one or more of a buffering agent, a surfactant, a bulking agent, and/or a preservative.
  • the amount of sucrose or maltose useful for stabilization of the lyophilized drug product may be in a weight ratio of at least 1:2 protein to sucrose or maltose.
  • the protein to sucrose or maltose weight ratio may be of from 1:2 to 1:5.
  • the pH of the formulation, prior to lyophilization may be set by addition of a pharmaceutically acceptable acid and/or base.
  • the pharmaceutically acceptable acid may be hydrochloric acid.
  • the pharmaceutically acceptable base may be sodium hydroxide.
  • a“bulking agent” may be added.
  • A“bulking agent” is a compound which adds mass to a lyophilized mixture and contributes to the physical structure of the lyophilized cake (e.g., facilitates the production of an essentially uniform lyophilized cake which maintains an open pore structure).
  • Illustrative bulking agents include mannitol, glycine, polyethylene glycol and sorbitol.
  • the lyophilized formulations of the present invention may contain such bulking agents.
  • a preservative may be optionally added to the formulations herein to reduce bacterial action.
  • the addition of a preservative may, for example, facilitate the production of a multi-use (multiple-dose) formulation.
  • Doses may be given once or more times daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the targetable construct or complex in bodily fluids or tissues.
  • Administration of the present invention could be intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intrapleural, intrathecal, intracavitary, by perfusion through a catheter or by direct intralesional injection. This may be administered once or more times daily, once or more times weekly, once or more times monthly, and once or more times annually.
  • Human cancer cell lines expressing HER2 were harvested from culture, cells were washed with HBS, and were resuspended in growth media at l0 6 /mL for labeling with BATDA reagent (Perkin Elmer AD0116). Manufacturer instructions were followed for labeling of the target cells. After labeling cells were washed 3x with HBS, and were resuspended at 0.5-1. Ox l0 5 /mL in culture media. To prepare the background wells an aliquot of the labeled cells was put aside, and the cells were spun out of the media. 100 pl of the media were carefully added to wells in triplicate to avoid disturbing the pelleted cells.
  • NK cells were harvested from culture, cells were washed, and were resuspended at l0 5 -2.0xl0 6 /mL in culture media depending on the desired E:T ratio. 50 m ⁇ of NK cells were added to each well of the plate to make a total of 200 m ⁇ culture volume. The plate was incubated at 37 °C with 5% C02 for 2- 3 hours before developing the assay.
  • NucLight Green expressing cells were harvested from culture, and were washed to remove residual selection antibiotic, cells were resuspended in fresh culture media and seeded into a 96 well flat bottom plate. The plate was placed in the IncuCyte S3 overnight to monitor cell attachment and growth. The next day human PBMCs were isolated using density gradient centrifugation, and A49-F3’-TriNKET-Trastuzumab or mAb dilutions were prepared in primary cell culture media. Diluted A49-F3’-TriNKET-Trastuzumab and mAbs were added to SkBr-3-NucLight Green cells, followed by freshly isolated PBMCs. The plate was then returned to the IncuCyte S3.
  • FIG. 3, FIG. 4, and FIG. 5 show TriNKET-mediated killing of three cell lines with different levels of HER2 expression. TriNKETs provided more potent, and higher maximal killing against all HER2-positive cells lines compared to the anti-HER2 monoclonal antibody trastuzumab.
  • FIG. 3 shows NK-mediated cell lysis of the HER2 1+ human cancer cell line 786-0. trastuzumab shows little activity against HER2 1+ cell lines, increasing specific lysis slightly higher than background killing. However, A49-F3’-TriNKET-Trastuzumab
  • scFv-Fc represented by SEQ ID NO: 140
  • an NKG2D-binding Fab fragment including a heavy chain portion comprising a heavy chain variable domain of ADI- 27749 (A49) (SEQ ID NO:94) and a CH1 domain, and a light chain portion comprising a light chain variable domain (SEQ ID NO:98) and a light chain constant domain, where the heavy chain variable domain is connected to the CH1 domain, and the CH1 domain is connected to the Fc domain (heavy chain portion represented as VH-CHl-Fc, amino acid sequence set forth in SEQ ID NO: 141)), and A44-F3’-KiH-TriNKET-Trastuzumab
  • scFv-Fc comprising SEQ ID NO: 139, linked to an Fc domain via a hinge comprising Ala-Ser (scFv-Fc represented by SEQ ID NO: 146), and an NKG2D- binding Fab fragment including a heavy chain portion comprising a heavy chain variable domain of ADI-27744 (A44) (SEQ ID NO:86) and a CH1 domain, and a light chain portion comprising a light chain variable domain (SEQ ID NO:90) and a light chain constant domain, where the heavy chain variable domain is connected to the CH1 domain, and the CH1 domain is connected to the Fc domain (heavy chain portion represented as VH-CHl-Fc, amino acid sequence set forth in SEQ ID NO: 148)) were more effective at targeting 786-0 cells, showing greater specific lysis than monoclonal antibody.
  • FIG. 4 demonstrates NK-mediated cell lysis of the human cancer cell line H661 with higher level of HER2 expression that the 786-0 cell line (denoted as HER2++).
  • trastuzumab Compared to the 786-0 cell line, trastuzumab showed improved killing against higher levels of HER2 expressed on H661 target cells. Despite improved lysis mediated by trastuzumab, A49-F3’-TriNKET-Trastuzumab still showed superior lysis of H661 target cells for both potency and maximal killing.
  • FIG. 5 shows NK-mediated cell lysis of the cancer cell line SkBr-3 with the highest level of HER2 expression among the three cell lines tested (denoted as HER2+++).
  • Trastuzumab showed increased potency against SkBr-3 cells compared to HER2+ and HER2++ cell lines, but A49-F3’-TriNKET-Trastuzumab still showed superior potency and maximal killing.
  • FIG. 6 and FIG. 7 show the effect of TriNKET or mAb on 72-hour co-cultures of human PBMCs and SkBr-3 HER2+ target cells.
  • SkBr-3 cells proliferated about 3-fold over a 72-hour period when cultured without effector PBMCs. Donor variability was evident in effector PBMCs.
  • PBMCs were added to SkBr-3 cultures, growth of the target SkBr-3 cells was nominally reduced (FIG. 6).
  • the addition of PBMC effector cells had negligible effect on SkBr-3 cell growth (FIG. 7).
  • the effector PBMCs When trastuzumab was added to the co-culture, the effector PBMCs had an increased ability to lyse target SkBr-3 cells, indicated as a decrease in % growth in FIG. 6 and FIG. 7.
  • A49-F3’-TriNKET- Trastuzumab (FIG. 6 and FIG. 7) and A44-F3’-KiH-TriNKET-Trastuzumab (FIG. 7) were added to the co-culture, the effector PBMCs were even more effective in lysing SkBr-3 target cells compared to trastuzumab, resulting in a faster and more complete reduction in SkBr-3 cells.
  • Trispecific -binding proteins TriNKETs
  • mAb monoclonal Ab
  • blood was washed 3x following incubation with TriNKET.
  • Directly labeled immunophenotyping mAbs and secondary antibody specific to trastuzumab were added to samples.
  • 2 mL of lx RBC lysis/fixation solution was added to each sample for 15 minutes at room temperature (RT), samples were then washed to remove red blood cells (RBCs). After washing, the samples were resuspended for FACS analysis.
  • FIGs. 8A-8F show binding of A49-F3’ -TriNKET - Trastuzumab (an NKG2D-binding domain from clone ADI- 27749; and an HER2-binding scFv comprising SEQ ID NO: 139, derived from trastuzumab monoclonal antibody) in whole human blood.
  • A49-F3’-TriNKET-Trastuzumab binding in human whole blood was the same as trastuzumab.
  • A49-F3’-TriNKET-Trastuzumab and trastuzumab demonstrated minimal binding to all populations of immune cells in blood. Small shifts were observed for trastuzumab and A49-F3’-TriNKET-Trastuzumab in both B cell and monocyte populations compared to secondary control samples. Binding observed on B cells and monocytes can likely be attributed to FcR interactions, rather than being Fab specific.
  • Human cardiomyocytes differentiated from induced pluripotent stem cells (Cellular Dynamics/Fuji Film), 786-0, H661 and SKBR3 cancer cells were used to evaluate binding of A49-F3’-TriNKET-Trastuzumab to these cells.
  • the human renal cell carcinoma cell line 786-0 expresses low levels of HER2, the human lung cancer cell line H661 expresses moderate levels of HER2, while the human breast cancer cell line SKBR3 expresses high levels of HER2.
  • TriNKETs were diluted to 3.8e-4 to 100 pg/mL, and the dilutions were used as primary antibody stain.
  • Binding of the TriNKET was detected using a fluorophore-conjugated anti-human IgG secondary antibody. Cells were analyzed by flow cytometry. Binding fluorescence intensity (MFI) to cells expressing HER2 was normalized to cells stained with a control (non-specific) TriNKET to obtain fold over background (FOB) values.
  • MFI fluorescence intensity
  • Image collection was setup on the IncuCyte S3. Image analysis was done using the IncuCyte S3 software. Masks for the green channel was created to count the number of tumor cells. Confluency of cardiomyocytes in the phase channel was used to assess cell viability and calculate % killing.
  • FIG. 10A shows A49-F3’-TriNKET-Trastuzumab-mediated human PBMC killing of SKBR3 cancer cells
  • FIG. 10B shows that A49-F3’-TriNKET-Trastuzumab did not kill non-malignant healthy cardiomyocytes after 3 days in co-culture at PBMC to target cell ratio (E:T) of 1:1.
  • FIG. 11A shows A49-F3’-TriNKET-Trastuzumab-mediated human PBMC killing of SKBR3 cancer cells
  • FIG. 11B shows that A49-F3’-TriNKET-Trastuzumab did not kill non-malignant healthy cardiomyocytes after 3 days in co-culture at E:T of 20:1.
  • Example 4 - TriNKETs trigger CD8+ T cell lysis of TAA+ tumor cells
  • Human PBMCs were isolated from human peripheral blood buffy coats using density gradient centrifugation. Isolated PBMCs were stimulated with 1 pg/m L Concanavalin A (ConA) at 37 °C for 18 hours. Then ConA was removed and cultured with 25 unit/mL IL-2 at 37 °C for 4 days. CD8+ T cells were purified using a negative selection technique with magnetic beads, then cultured in media containing 25 unit/mL IL-2 or 10 ng/mL IL-15 at 37 °C for 8-10 days.
  • ConA Concanavalin A
  • SkBr-3 Human cancer cell line SkBr-3 expressing a target of interest, HER2, was labeled with BacMam 3.0 NucLight Green (#4622) to allow for tracking of the target cells.
  • SkBr-3 target cells were harvested from culture, washed, resuspended in growth media, and plated at 5,000/well in a 96-well plate. The plate was incubated at 37 °C with 5% C0 2 overnight. Monoclonal antibodies, TriNKETs and controls were diluted in culture media; 50 pl of diluted mAb or TriNKET were added to each well.
  • CD8+ T cells generated with conA stimulation and cultured with IL-15 were of high purity (99% of CD3+CD8+ cells), and all expressed NKG2D but not CD16 (FIGs. 12A- 12C). Similar results are observed with CD8+ T cells generated with IL-2 culture.
  • Trastuzumab showed a higher binding affinity than the TriNKET (A49-F3’- TriNKET-Trastuzumab ) with each of the three cell lines (SkBr-3 (FIG. 15A), NCTH661 (FIG. 16A), and 786-0 (FIG. 17A)).
  • FOB fold over background
  • the maximum binding of the TriNKET to each of the three cell lines was greater than the maximum binding of trastuzumab (SkBr-3 (FIGs. 15B), NCTH661 (FIG. 16B), and 786-0 (FIG. 17B)).
  • the difference was especially significant with the SkBr-3 cells, which had a high HER2 expression level (FIG. 15B).
  • PBMCs were isolated from human peripheral blood buffy coats using density gradient centrifugation and were washed.
  • NK cells were isolated from the PBMCs using a negative selection technique with magnetic beads. Typically, with this technique, more than 90% of the harvested cells were CD3 CD56 + .
  • the isolated NK cells were rested overnight. Rested NK cells were used the following day in cytotoxicity assays.
  • Human cancer cell lines expressing a target of interest were harvested from culture. The cells were washed with HBS, and were resuspended in growth media at 10 6 cells/mL for labeling with BATDA reagent (Perkin Elmer AD0116). Manufacturer instructions were followed for labeling of the target cells. After labeling, the cells were washed three times with HBS, and were resuspended at 0.5-l.0xl0 5 /mL in culture media. 100 pl of BATDA labeled cells were added to each well of the 96-well plate.
  • Trastuzumab and A49-F3’ -TriNKET -Trastuzumab was diluted in culture media, and 50 pl of diluted trastuzumab and A49-F3’-TriNKET-Trastuzumab were added, respectively, to each of their corresponding wells for the experiment.
  • Rested and/or activated NK cells were harvested from culture. The cells were washed and resuspended at l0 5 -2.0xl0 6 /mL in culture media depending on the desired E:T ratio. 50 pl of NK cells were added to each well of the plate to make a total of 200 m ⁇ culture volume.
  • TriNKET exhibited a significant advantage in potency and maximum lysis of target cells compared to the combination of Fc-silent TriNKET and trastuzumab, when the target cells were 786-0 cells (FIG. 19) or H661 cells (FIG. 20).
  • ADI- 27749 contains, inter alia, a heavy chain CDR3 having the amino acid sequence of GAPMGAAAGWFDP (SEQ ID NO: 169).
  • the Met at position 102 of SEQ ID NO:94 i.e . , at position 4 of this CDR3 sequence
  • TriNKET A Binding of A49-F3’-TriNKET-Trastuzumab (“TriNKET A”) and a mutant form of TriNKET A having a substitution of Ile for the Met (“TriNKET A*”) to a fusion protein of human NKG2D and murine Fc (“mFc-hNKG2D”) was characterized by surface plasmon resonance (SPR) at 37 °C. Steady state affinity fit was utilized to obtain the equilibrium affinity data. The equilibrium affinity constants were calculated, and data from two independent experiments for TriNKET A* and the independent experiments for TriNKET A were averaged.
  • SPR surface plasmon resonance
  • the equilibrium affinity constant (KD) obtained from the affinity fit was very similar between the replicates, which suggested a high confidence in the measured parameters.
  • the KD values indicated that the M102 variant has less than 2-fold reduced affinity for human NKG2D compared to TriNKET A.
  • the KD for TriNKET A* was (4.81+0.39) x HE 7 M, while the K D for TriNKET A was (3.37+0.30) x KG 7 M (calculated from the affinity fit).
  • KD values suggested that the M102 mutation had only a minor effect on the binding of an A49-containing TriNKET to human NKG2D.
  • KHYG-l cells expressing the high-affinity variant of CDl6a were generated through retroviral transduction. Following transduction, cells were selected in puromycin-containing growth media to generate a selected population of KHYG-l -CD 16V cells. The selected population was maintained in media containing 10 ng/mL human IL-2.
  • the cells were harvested from culture, pelleted, washed three times in culture media without IL-2, and resuspended in culture media without IL-2 and rested for 24 hours.
  • SKBR-3 expressing the tumor antigen HER2 were selected as target cells.
  • SKBR-3 expressing HER2 were harvested from culture. The cells were washed with Hepes Buffered Saline (HBS), and were resuspended in growth media at 10 6 cells/mL for labeling with BATDA (hydrophobic esterified form of TDA (bis(acetoxymethyl) 2,2':6',2"-terpyridine- 6,6"-dicarboxylate) reagent (Perkin Elmer Cl 36- 100) (BATDA diffuses through the cell membrane of viable cells, and is hydrolyzed by intracellular esterases resulting in
  • TDA membrane permeable TDA
  • the TDA released from lysed cells into the supernatant is chelated with Eu3+, and the NK cell activity is quantified by measuring the intense fluorescence of the EuTDA chelate formed.
  • Manufacturer instructions were followed for labeling of the target cells. After labeling, the cells were washed three times with HBS and were resuspended at 0.5xl0 5 cells /mL in culture media. 100 m ⁇ of BATDA labeled cells were added to each well of a 96-well plate.
  • TriNKETs were serially diluted in culture media, and 50 m ⁇ of a diluted TriNKET were added to each well.
  • Rested NK cells were harvested from culture, washed, and resuspended at l.OxlO 6 cells/mL in culture media.
  • 50 m ⁇ of NK cells were added to each well of the plate to attain a desired E:T ratio of 10: 1 and to make a total of 200 m ⁇ culture volume in each well. The plate was incubated at 37 °C with 5% C0 2 for 2-3 hours.
  • % specific lysis ((Experimental release - Spontaneous release) / (Maximum release - Spontaneous release)) x 100%.
  • Embodiments disclosed herein include embodiments Pl to P49, as provided in the numbered embodiments of the disclosure:
  • Embodiment Pl A protein comprising: (a) a first antigen -binding site comprising an Fab fragment that binds NKG2D; (b) a second antigen-binding site comprising a single chain variable fragment (scFv) that binds HER2; and (c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16.
  • scFv single chain variable fragment
  • Embodiment P2 The protein of embodiment Pl, wherein the scFv is linked to the antibody Fc domain or a portion thereof sufficient to bind CD 16, or the third antigen -binding site that binds CD 16, via a hinge comprising Ala-Ser, wherein the scFv comprises a heavy chain variable domain and a light chain variable domain.
  • Embodiment P3 The protein according to embodiment P2, wherein the scFv is linked to the antibody Fc domain.
  • Embodiment P4 The protein according to embodiment P2 or P3, wherein the heavy chain variable domain of the scFv forms a disulfide bridge with the light chain variable domain of the scFv.
  • Embodiment P5 The protein according to embodiment P4, wherein the disulfide bridge is formed between C44 from the heavy chain variable domain and C100 from the light chain variable domain.
  • Embodiment P6 The protein according to embodiment P5, wherein the scFv is linked to the antibody Fc domain, wherein the light chain variable domain of the scFv is positioned at the N-terminus of the heavy chain variable domain of the scFv, and is linked to the heavy chain variable domain of the scFv via a flexible linker (GlyGlyGlyGlySer)4 ((G4S)4) (SEQ ID NO:203), and the Fab is linked to the antibody Fc domain.
  • a flexible linker GlyGlyGlyGlySer 4 ((G4S)4)
  • Embodiment P7 The protein according to any one of embodiments P2-P6, wherein the heavy chain variable domain of the scFv is linked to the light chain variable domain of the scFv via a flexible linker.
  • Embodiment P8 The protein according to embodiment P7, wherein the flexible linker comprises (GlyGlyGlyGlySer)4 ((G4S)4) (SEQ ID NO:203).
  • Embodiment P9 The protein according to any one of embodiments P2-P8, wherein the heavy chain variable domain of the scFv is positioned at the N-terminus or the C- terminus of the light chain variable domain of the scFv.
  • Embodiment P10 The protein according to embodiment P9, wherein the light chain variable domain of the scFv is positioned at the N-terminus of the heavy chain variable domain of the scFv.
  • Embodiment Pl 1 The protein according to any one of embodiments Pl to P10, wherein the Fab fragment is linked to the antibody Fc domain or a portion thereof sufficient to bind CD 16 or the third antigen-binding site that binds CD 16.
  • Embodiment P12 The protein according to embodiment Pl 1, wherein the heavy chain portion of the Fab fragment comprises a heavy chain variable domain and a CH1 domain, and wherein the heavy chain variable domain is linked to the CH1 domain.
  • Embodiment P13 The protein according to embodiment Pl 1 or P12, wherein the Fab is linked to the antibody Fc domain.
  • Embodiment P14 A protein according to any of the preceding embodiments comprising a sequence of SEQ ID NO: 139.
  • Embodiment P15 A protein according to any one of embodiments P2-P14 comprising an scFv linked to an antibody Fc domain, wherein the scFv linked to the antibody Fc domain is represented by a sequence selected from SEQ ID NO: 140 and SEQ ID NO: 146.
  • Embodiment P16 A protein according to any of the preceding embodiments comprising a sequence of SEQ ID NO: 141, SEQ ID NO: 145, SEQ ID NO: 147, or SEQ ID NO: l48.
  • Embodiment P17 A protein comprising a sequence at least 90% identical to an amino acid sequence of SEQ ID NO: 139.
  • Embodiment P18 A protein comprising a sequence at least 95% identical to an amino acid sequence of SEQ ID NO: 139.
  • Embodiment P19 A protein comprising a sequence at least 99% identical to an amino acid sequence of SEQ ID NO: 139.
  • Embodiment P20 A protein comprising a sequence at least 90% identical to an amino acid sequence selected from SEQ ID NO: 140 and SEQ ID NO: 146.
  • Embodiment P21 A protein comprising a sequence at least 95% identical to an amino acid sequence selected from SEQ ID NO: 140 and SEQ ID NO: 146.
  • Embodiment P22 A protein comprising a sequence at least 99% identical to an amino acid sequence selected from SEQ ID NO: 140 and SEQ ID NO: 146.
  • Embodiment P23 The protein according any one of embodiments P1-P13, wherein the first antigen-binding site that binds NKG2D comprises a heavy chain variable domain at least 90% identical to an amino acid sequence selected from SEQ ID NO:86 and SEQ ID NO:94.
  • Embodiment P24 The protein according any one of embodiments P1-P13, wherein the first antigen-binding site that binds NKG2D comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:86 and a light chain variable domain at least 90% identical to SEQ ID NO:90.
  • Embodiment P25 The protein according any one of embodiments P1-P13, wherein the first antigen-binding site that binds NKG2D comprises a heavy chain variable domain at least 95% identical to SEQ ID NO:86 and a light chain variable domain at least 95% identical to SEQ ID NO:90.
  • Embodiment P26 The protein according any one of embodiments P1-P13, wherein the first antigen-binding site that binds NKG2D comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:94 and a light chain variable domain at least 90% identical to SEQ ID NO:98.
  • Embodiment P27 The protein according any one of embodiments P1-P13, wherein the first antigen-binding site that binds NKG2D comprises a heavy chain variable domain at least 95% identical to SEQ ID NO:94 and a light chain variable domain at least 95% identical to SEQ ID NO:98.
  • Embodiment P28 The protein according any one of embodiments P1-P13, wherein the first antigen-binding site that binds NKG2D comprises a heavy chain variable domain at least 90% identical to SEQ ID NO: 144 and a light chain variable domain at least 90% identical to SEQ ID NO:98.
  • Embodiment P29 The protein according any one of embodiments P1-P13, wherein the first antigen-binding site that binds NKG2D comprises a heavy chain variable domain at least 95% identical to SEQ ID NO: 144 and a light chain variable domain at least 95% identical to SEQ ID NO:98.
  • Embodiment P30 The protein according any one of embodiments P1-P13, wherein the first antigen-binding site that binds NKG2D comprises a heavy chain variable domain identical to SEQ ID NO:86 and a light chain variable domain identical to SEQ ID NO:90.
  • Embodiment P31 The protein according any one of embodiments P1-P13, wherein the first antigen-binding site that binds NKG2D comprises a heavy chain variable domain identical to SEQ ID NO:94 and a light chain variable domain identical to SEQ ID NO:98.
  • Embodiment P32 The protein according any one of embodiments P1-P13, wherein the first antigen-binding site that binds NKG2D comprises a heavy chain variable domain identical to SEQ ID NO: 144 and a light chain variable domain identical to SEQ ID NO:98.
  • Embodiment P33 The protein according any one of embodiments P1-P13 and P23-P32, wherein the antibody Fc domain comprises hinge and CH2 domains of a human IgGl antibody.
  • Embodiment P34 The protein according to embodiment P33, wherein the Fc domain comprises an amino acid sequence at least 90% identical to amino acids 234-332 of a human IgGl antibody.
  • Embodiment P35 The protein according to embodiment P33 or P34, wherein the Fc domain comprises amino acid sequence at least 90% identical to the Fc domain of human IgGl and differs at one or more positions selected from the group consisting of Q347, Y349, T350, L351, S354, E356, E357, K360, Q362, S364, T366, L368, K370, N390, K392, T394, D399, S400, D401, F405, Y407, K409, T411, K439.
  • Embodiment P36 The protein according to any one of embodiments P1-P13 and P23-P34, wherein the Fc domain is an Fc domain of a human IgGl comprising Q347R, D399V, and F405T substitutions.
  • Embodiment P37 The protein according to embodiment P36, wherein the Fc domain comprising the substitutions is linked to the scFv.
  • Embodiment P38 The protein according to any one of embodiments P1-P13 and P23-P34, wherein the Fc domain is an Fc domain of a human IgGl comprising K360E and K409W substitutions.
  • Embodiment P39 The protein according to embodiment P38, wherein the Fc domain comprising the substitutions is linked to the Fab fragment.
  • Embodiment P40 The protein according to any one of embodiments P1-P13 and P23-P34, wherein the Fc domain is an Fc domain of a human IgGl comprising a T366W substitution.
  • Embodiment P41 The protein according to embodiment P40, wherein the Fc domain comprising the substitution is linked to the Fab fragment.
  • Embodiment P42 The protein according to any one of embodiments P1-P13 and P23-P34, wherein the Fc domain is an Fc domain of a human IgGl comprising T366S, F368A, and Y407V substitutions.
  • Embodiment P43 The protein according to embodiment P42, wherein the Fc domain comprising the substitutions is linked to the scFv.
  • Embodiment P44 A protein according to any one of embodiments P1-P43, wherein the protein binds to NKG2D with an affinity of KD of 10 nM or lower.
  • Embodiment P45 A formulation comprising a protein according to any one of the preceding embodiments and a pharmaceutically acceptable carrier.
  • Embodiment P46 A cell comprising one or more nucleic acids expressing a protein according to any one of embodiments P1-P44.
  • Embodiment P47 A method of directly and/or indirectly enhancing tumor cell death, the method comprising exposing a tumor and natural killer cells to a protein according to any one of embodiments P1-P44.
  • Embodiment P48 A method of treating cancer, wherein the method comprises administering a protein according to any one of embodiments P1-P44 or a formulation according to embodiment P45 to a patient.
  • Embodiment P49 The method of embodiment P48, wherein the cancer is selected from the group consisting of breast cancer, thyroid cancer, gastric cancer, renal cell carcinoma, adenocarcinoma of the lung, prostate cancer, cholangiocarcinoma, uterine cancer, pancreatic cancer, colorectal cancer, ovarian cancer, cervical cancer, head and neck cancer, lung squamous, mesothelioma, liver cancer, mesothelioma, sarcoma, and gall bladder cancer.
  • the cancer is selected from the group consisting of breast cancer, thyroid cancer, gastric cancer, renal cell carcinoma, adenocarcinoma of the lung, prostate cancer, cholangiocarcinoma, uterine cancer, pancreatic cancer, colorectal cancer, ovarian cancer, cervical cancer, head and neck cancer, lung squamous, mesothelioma, liver cancer, mesothelioma, sarcoma, and gall bladder cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/US2019/045561 2018-08-08 2019-08-07 Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use Ceased WO2020033587A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
CN201980061436.2A CN112770769B (zh) 2018-08-08 2019-08-07 结合her2、nkg2d和cd16的多特异性结合蛋白及其使用方法
KR1020217006243A KR102645411B1 (ko) 2018-08-08 2019-08-07 Her2, nkg2d 및 cd16에 결합하는 다중-특이적 결합 단백질 및 사용 방법
EA202190453A EA202190453A1 (ru) 2018-08-08 2019-08-07 Полиспецифические связывающие белки, которые связываются с her2, nkg2d и cd16, и способы их применения
MX2021001508A MX2021001508A (es) 2018-08-08 2019-08-07 Proteínas de unión multiespecífica que se unen a her2, nkg2d y cd16 y métodos de uso.
DK19847982.6T DK3833386T5 (da) 2018-08-08 2019-08-07 Multispecifikke bindende proteiner, der binder her2, nkg2d og cd16, og anvendelsesmetoder
BR112021002213-9A BR112021002213A2 (pt) 2018-08-08 2019-08-07 proteínas de ligação multi-específicas que se ligam her2, nkg2d e cd16 e métodos de uso
SG11202101276QA SG11202101276QA (en) 2018-08-08 2019-08-07 Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
IL280656A IL280656B2 (en) 2018-08-08 2019-08-07 Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
US17/265,876 US12275791B2 (en) 2018-08-08 2019-08-07 Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
FIEP19847982.6T FI3833386T3 (fi) 2018-08-08 2019-08-07 Monispesifisiä sitoutuvia proteiineja, jotka sitovat her2:ta, nkg2d:tä ja cd16:ta, ja käyttömenetelmiä
CA3108794A CA3108794A1 (en) 2018-08-08 2019-08-07 Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
EP19847982.6A EP3833386B1 (en) 2018-08-08 2019-08-07 Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
MYPI2021000690A MY201987A (en) 2018-08-08 2019-08-07 Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
JP2021506447A JP7431394B2 (ja) 2018-08-08 2019-08-07 Ｈｅｒ２、ｎｋｇ２ｄおよびｃｄ１６に結合する多重特異性結合タンパク質ならびに使用方法
ES19847982T ES2954851T3 (es) 2018-08-08 2019-08-07 Proteínas de unión multiespecífica que se unen a HER2, NKG2D y CD16, y métodos de uso
EP23170653.2A EP4249067A3 (en) 2018-08-08 2019-08-07 Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
AU2019318425A AU2019318425B2 (en) 2018-08-08 2019-08-07 Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
ZA2021/00916A ZA202100916B (en) 2018-08-08 2021-02-10 Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
US19/076,034 US20250206827A1 (en) 2018-08-08 2025-03-11 Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862716259P 2018-08-08 2018-08-08
US62/716,259 2018-08-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US17/265,876 A-371-Of-International US12275791B2 (en) 2018-08-08 2019-08-07 Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
US19/076,034 Continuation US20250206827A1 (en) 2018-08-08 2025-03-11 Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use

Publications (1)

Publication Number Publication Date
WO2020033587A1 true WO2020033587A1 (en) 2020-02-13

Family

ID=69413631

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/045561 Ceased WO2020033587A1 (en) 2018-08-08 2019-08-07 Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use

Country Status (19)

Country Link
US (2) US12275791B2 (https=)
EP (2) EP3833386B1 (https=)
JP (1) JP7431394B2 (https=)
KR (1) KR102645411B1 (https=)
CN (1) CN112770769B (https=)
AU (1) AU2019318425B2 (https=)
BR (1) BR112021002213A2 (https=)
CA (1) CA3108794A1 (https=)
DK (1) DK3833386T5 (https=)
EA (2) EA202091888A1 (https=)
ES (1) ES2954851T3 (https=)
FI (1) FI3833386T3 (https=)
IL (1) IL280656B2 (https=)
MX (1) MX2021001508A (https=)
MY (1) MY201987A (https=)
SA (1) SA521421188B1 (https=)
SG (1) SG11202101276QA (https=)
WO (1) WO2020033587A1 (https=)
ZA (1) ZA202100916B (https=)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021224913A1 (en) * 2020-05-04 2021-11-11 Immunorizon Ltd. Precursor tri-specific antibody constructs and methods of use thereof
JP2022546454A (ja) * 2019-08-30 2022-11-04 ドラゴンフライ セラピューティクス， インコーポレイテッド がん処置のためのｈｅｒ２、ｎｋｇ２ｄおよびｃｄ１６に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン
JP2024508894A (ja) * 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
US11939384B1 (en) 2018-02-08 2024-03-26 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US12145976B2 (en) 2018-03-27 2024-11-19 Xyphos Biosciences Inc. Modified A1-A2 domains of non-natural NKG2D ligands that bind non-natural NKG2D receptors
US12275791B2 (en) 2018-08-08 2025-04-15 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
US12384851B2 (en) 2018-08-08 2025-08-12 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
EP4476263A4 (en) * 2022-02-09 2026-01-28 Dragonfly Therapeutics Inc PHARMACEUTICAL FORMULATIONS AND THERAPEUTIC USES OF MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO EGFR, NKG2D AND CD16

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
IL268755B2 (en) 2017-02-20 2025-12-01 Dragonfly Therapeutics Inc Proteins that bind her2, nkg2d, and cd16
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
MX2022014208A (es) * 2020-05-21 2022-12-07 Merus Nv Metodos y medios para la produccion de moleculas tipo ig.
CN116023501A (zh) * 2021-10-25 2023-04-28 三生国健药业（上海）股份有限公司 一种抗her2的免疫毒素分子、及其制备方法与应用
AU2023361491A1 (en) * 2022-10-12 2025-05-08 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
GB202412004D0 (en) * 2024-08-14 2024-09-25 Cytospire Therapeutics Ltd Novel conditional immunoconjugates

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002905A1 (en) 2005-06-29 2007-01-04 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
US20150210765A1 (en) * 2011-05-24 2015-07-30 Zyngenia, Inc. Multivalent and Monovalent Multispecific Complexes and Their Uses
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
WO2016090278A2 (en) 2014-12-05 2016-06-09 Avidbiotics Corp. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
WO2016134371A2 (en) 2015-02-20 2016-08-25 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
WO2016196237A1 (en) * 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2017081190A1 (en) 2015-11-13 2017-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
US20170291955A1 (en) * 2014-04-11 2017-10-12 Medlmmune, Llc Bispecific her2 antibodies
US20170368169A1 (en) * 2016-03-21 2017-12-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2018119171A1 (en) * 2016-12-23 2018-06-28 Potenza Therapeutics, Inc. Anti-neuropilin antigen-binding proteins and methods of use thereof
WO2018152518A1 (en) 2017-02-20 2018-08-23 Adimab, Llc Proteins binding her2, nkg2d and cd16
WO2019157332A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
WO2019157366A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
WO2019231920A1 (en) 2018-05-28 2019-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins and improvements thereon

Family Cites Families (299)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366707A1 (en) 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
WO1989006544A1 (en) 1988-01-15 1989-07-27 Centocor, Inc. Heteroligating antibodies and therapeutic uses thereof
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU5509296A (en) 1995-05-03 1996-11-21 Colin Henry Self Bispecific antibodies in which the binding capability is rev ersibly inhibited by a photocleavable moiety
DE19531346A1 (de) 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
CZ302070B6 (cs) 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
ES2293748T3 (es) 1998-10-21 2008-03-16 Altor Bioscience Corporation Moleculas de fijacion poliespecificas y usos de las mismas.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CN1423700A (zh) 2000-03-24 2003-06-11 麦克美特股份公司 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽
EP1299419A2 (en) 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
US20040115198A1 (en) 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
CA2496419A1 (en) 2002-08-19 2004-02-26 Abgenix, Inc. Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
DE10261223A1 (de) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
AU2004210088A1 (en) 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring T cell response
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
SI1629011T1 (sl) 2003-05-31 2010-05-31 Micromet Ag Humane molekule za vezavo anti hu cd
ES2393485T3 (es) 2003-07-02 2012-12-21 Innate Pharma Anticuerpos del receptor de NK pan-kir2dl y su uso en diagnóstico y terapia
US7803376B2 (en) * 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
DK1716178T3 (da) 2004-02-16 2010-09-20 Micromet Ag Mindre immunogene bindingsmolekyler
WO2005105849A1 (en) 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for treating proliferative disorders such as nk-type ldgl
AU2005263555B2 (en) 2004-07-16 2011-01-27 Amgen Research (Munich) Gmbh Expression-enhanced polypeptides
KR20140032004A (ko) 2004-07-22 2014-03-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
AU2005291039A1 (en) 2004-10-01 2006-04-13 Avidex Ltd. T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
EP1928495A2 (en) 2005-08-19 2008-06-11 Cerus Corporation Antibody-mediated enhancement of immune response
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
AU2006301163B2 (en) 2005-10-14 2012-02-23 Innate Pharma Compositions and methods for treating proliferative disorders
WO2007048849A1 (en) 2005-10-28 2007-05-03 Novo Nordisk A/S Fusion proteins that bind effector lymphocytes and target cells
EP1945674A2 (en) 2005-11-03 2008-07-23 Genentech, Inc. Therapeutic anti-her2 antibody fusion polypeptides
EP1949107A1 (en) 2005-11-03 2008-07-30 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by nkg2d-positive cd4-positive cells
DK1976886T3 (en) 2005-12-16 2015-03-02 Amgen Res Munich Gmbh Means and methods for the treatment of tumor diseases
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
JP5161882B2 (ja) 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
EP1900752A1 (en) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
CN101269760B (zh) 2007-03-23 2011-11-16 海德堡印刷机械股份公司 收纸滚筒及双面印刷机
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2183028A2 (en) 2007-07-25 2010-05-12 AstraZeneca AB Targeted binging agents directed to kdr and uses thereof - 035
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
KR101615935B1 (ko) 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
MX2010008025A (es) 2008-01-22 2010-08-04 Biogen Idec Inc Anticuerpos ron y usos de los mismos.
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
US8067339B2 (en) 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
EP2352758A2 (en) 2008-09-26 2011-08-10 Wyeth LLC Single chain antibody library design
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
WO2010080124A2 (en) 2008-12-18 2010-07-15 Dana-Farber Cancer Institute, Inc. Nkg2d-fc for immunotherapy
EP2376109B1 (en) 2008-12-19 2019-01-23 MacroGenics, Inc. Covalent diabodies and uses thereof
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
WO2010132697A2 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treatment
US20130209514A1 (en) 2009-06-09 2013-08-15 Eli Gilboa Aptamer-targeted costimulatory ligand aptamer
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
SG177560A1 (en) 2009-07-06 2012-03-29 Hoffmann La Roche Bi-specific digoxigenin binding antibodies
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US9062287B2 (en) 2009-09-11 2015-06-23 Takara Bio Inc. Process for production of natural killer cells
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
CN107227335A (zh) 2009-10-27 2017-10-03 安进研发（慕尼黑）股份有限公司 用于施用CD19xCD3双特异性抗体的给药方案
WO2011057124A1 (en) 2009-11-06 2011-05-12 Transtarget, Inc. Polyclonal bispecific antibody compositions and method of use
EP2332994A1 (en) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
WO2011075636A2 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
WO2011085178A1 (en) 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CN102946906B (zh) 2010-04-23 2015-07-15 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
DK3323830T3 (da) 2010-06-19 2023-09-25 Memorial Sloan Kettering Cancer Center Anti-gd2 antibodies
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
DE102010039018B4 (de) 2010-08-06 2013-02-28 Technische Universität Dresden Anti-La Antikörper und ihre Anwendung zum Immunotargeting
CA2808154A1 (en) 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
JP5866130B2 (ja) 2010-09-10 2016-02-17 アペクシジェン， インコーポレイテッド 抗ＩＬ−１β抗体およびその使用方法
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US20120263722A1 (en) 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CA2817015A1 (en) 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
EP2686345B1 (en) 2011-03-16 2018-04-25 Amgen Inc. Fc variants
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
CA2836873C (en) 2011-05-21 2019-10-22 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
US20140234342A1 (en) 2011-06-21 2014-08-21 Innate Pharma Nkp46-mediated nk cell tuning
CN109517059B (zh) 2011-06-30 2023-03-28 中外制药株式会社 异源二聚化多肽
DE102011118022B4 (de) 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP5938473B2 (ja) 2011-07-22 2016-06-22 アフィメート テラポイティクス アーゲー 多価抗原結合Ｆｖ分子
WO2013036799A2 (en) 2011-09-09 2013-03-14 Fred Hutchinson Cancer Research Center Methods and compositions involving nkg2d inhibitors and cancer
RU2732151C2 (ru) 2011-09-30 2020-09-11 Чугаи Сейяку Кабусики Кайся Библиотека зависимых от концентрации ионов связывающих молекул
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
LT2794658T (lt) 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
TWI606064B (zh) 2012-02-08 2017-11-21 Ｉｇｍ生物科技公司 細胞死亡誘導分子（ｃｄｉｍ）結合蛋白類及彼等之用途
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9029510B2 (en) 2012-03-30 2015-05-12 Sorrento Therapeutics, Inc. Fully human antibodies that bind to VEGFR2 and methods of use thereof
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
EP3795215A1 (en) 2012-05-30 2021-03-24 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
WO2013192594A2 (en) 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
WO2014012085A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
US9610332B2 (en) * 2012-07-18 2017-04-04 Massachusetts Institute Of Technology Compositions and methods for modulating BRD4 bioactivity
US20140072581A1 (en) 2012-07-23 2014-03-13 Zymeworks Inc. Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
EP3470431A1 (en) 2012-09-27 2019-04-17 Merus N.V. Bispecific igg antibodies as t cell engagers
CN104271602B (zh) 2012-11-21 2020-08-21 武汉友芝友生物制药有限公司 双特异性抗体
EP3878964A1 (en) 2012-11-27 2021-09-15 Ajou University Industry-Academic Cooperation Foundation Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
WO2014100490A1 (en) 2012-12-19 2014-06-26 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
KR20200024345A (ko) 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
US10309969B2 (en) * 2013-01-24 2019-06-04 Abtlas Co., Ltd. Protein combination-based FV library, and preparation method therefor
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
US10047163B2 (en) 2013-02-08 2018-08-14 Abbvie Stemcentrx Llc Multispecific constructs
MX375359B (es) 2013-02-26 2025-03-06 Roche Glycart Ag Moléculas biespecíficas de unión a antígeno activadoras de células t.
JP6676521B2 (ja) 2013-03-14 2020-04-08 マクロジェニクス，インコーポレーテッド 二重特異性分子、薬学的組成物及びそれらの使用
CA2902739C (en) * 2013-03-15 2022-11-22 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10047167B2 (en) 2013-03-15 2018-08-14 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
CN105705165B (zh) 2013-03-15 2020-04-24 纪念斯隆-凯特琳癌症中心 高亲和力抗gd2抗体
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
US20140323315A1 (en) 2013-04-29 2014-10-30 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
EP3415534A1 (en) 2013-05-10 2018-12-19 Numab Therapeutics AG Bispecific constructs and their use in the treatment of various diseases
EP3008093A1 (en) 2013-06-11 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
US9908944B2 (en) 2013-07-15 2018-03-06 Novo Nordisk A/S Antibodies that bind urokinase plasminogen activator
CA2916681A1 (en) 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
GB2518221A (en) 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
EP3046938B1 (en) 2013-09-16 2019-12-04 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
JP6553069B2 (ja) 2013-11-07 2019-07-31 メモリアル スローン ケタリング キャンサー センター 抗ｗｔ１／ｈｌａ二重特異性抗体
DE102013019352A1 (de) 2013-11-13 2015-09-17 Elke Pogge Von Strandmann Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort
HRP20250551T1 (hr) 2013-11-27 2025-06-20 Zymeworks Bc Inc. Bispecifični antigen-vezujući konstrukti koji ciljaju her2
EA201691214A1 (ru) 2013-12-13 2016-12-30 Дженентек, Инк. Антитела к cd33 и иммуноконъюгаты
EP3083682B1 (en) 2013-12-20 2024-04-17 F. Hoffmann-La Roche AG Dual specific antibodies
EP3327038B1 (en) 2013-12-20 2020-09-23 F. Hoffmann-La Roche AG Bispecific her2 antibodies and methods of use
SG11201605093VA (en) 2013-12-23 2016-07-28 Zymeworks Inc Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof
BR112016015140A2 (pt) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
US20160326249A1 (en) 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
CN112094347A (zh) 2014-03-05 2020-12-18 奥托路斯有限公司 具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
EP3126384B1 (en) 2014-04-01 2020-12-02 Adimab, LLC Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
EP2942629A1 (en) 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
CA2952532A1 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific antigen binding proteins
JP6822849B2 (ja) 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
BR112016030740A2 (pt) 2014-07-01 2018-02-20 Pfizer Inc. diacorpos heterodiméricos biespecíficos e seus usos
US9777073B2 (en) 2014-07-21 2017-10-03 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody EpCAM×CD3
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
WO2016011571A1 (en) 2014-07-21 2016-01-28 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
JP6390239B2 (ja) 2014-07-25 2018-09-19 富士ゼロックス株式会社 情報処理装置、及びプログラム
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
JP2017533255A (ja) 2014-08-28 2017-11-09 アカデミス・ジーケンハイス・ライデン・ハー・オー・デー・エヌ・エルユーエムセーＡｃａｄｅｍｉｓｃｈ Ｚｉｅｋｅｎｈｕｉｓ Ｌｅｉｄｅｎ Ｈ．Ｏ．Ｄ．Ｎ． Ｌｕｍｃ Ｃｄ９４／ｎｋｇ２ａおよび／またはｃｄ９４／ｎｋｇ２ｂ抗体、ワクチンの組み合わせ
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
EP3215531A1 (en) 2014-11-03 2017-09-13 Merck Patent GmbH Methods for generating bispecific shark variable antibody domains and use thereof
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
CA2970255A1 (en) 2014-12-17 2016-06-23 Intrexon Corporation Intercalated single-chain variable fragments
US10941207B2 (en) 2014-12-19 2021-03-09 Chiome Bioscience, Inc Fusion protein comprising three binding domains to 5T4 and CD3
JP6744313B2 (ja) 2015-01-02 2020-08-26 ダイアックス コーポレーション 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
AR100680A1 (es) 2015-01-26 2016-10-26 Macrogenics Inc Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos
MA41613A (fr) 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US11673957B2 (en) 2015-03-10 2023-06-13 Eureka Therapeutics, Inc. Anti-ROR2 antibodies
JP6726676B2 (ja) 2015-03-16 2020-07-22 ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ Ｍｕｅｎｃｈｅｎ Ｄｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） Ｈｂｖ感染および関連症状を治療するための三重特異的結合分子
AU2016243026B2 (en) 2015-04-03 2022-03-31 Eureka Therapeutics, Inc. Constructs targeting AFP peptide/MHC complexes and uses thereof
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
EP3842072A1 (en) 2015-05-18 2021-06-30 Eureka Therapeutics, Inc. Anti-ror1 antibodies
EP3095792A1 (en) 2015-05-19 2016-11-23 Klinikum rechts der Isar der Technischen Universität München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
US20180147257A1 (en) 2015-05-22 2018-05-31 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
TN2019000101A1 (en) 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
CN107708741A (zh) 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
WO2016207278A1 (en) 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
DK3313876T3 (da) 2015-06-23 2025-04-22 Innate Pharma Multispecifikke antigenbindende proteiner
CA2991264C (en) 2015-07-06 2023-10-10 Ucb Biopharma Sprl Tau-binding antibodies
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
WO2017008169A1 (en) 2015-07-15 2017-01-19 Zymeworks Inc. Drug-conjugated bi-specific antigen-binding constructs
HK1255234A1 (zh) 2015-07-16 2019-08-09 塞勒兰特治疗公司 经半胱氨酸取代的免疫球蛋白
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EP3349792A1 (en) 2015-09-14 2018-07-25 Compass Therapeutics LLC Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-
PE20240096A1 (es) 2015-10-02 2024-01-18 Hoffmann La Roche Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
KR101851380B1 (ko) 2015-10-12 2018-04-23 아주대학교산학협력단 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
CA3003458A1 (en) 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
EP4074731A1 (en) 2015-11-04 2022-10-19 City of Hope Chimeric antigen receptors targeting her2
US10815290B2 (en) 2015-11-10 2020-10-27 Fred Hutchinson Cancer Research Center NKG2D decoys
CN115925933A (zh) 2015-12-28 2023-04-07 依奈特制药公司 NKp46结合蛋白的可变区
MA43874A (fr) 2016-01-13 2018-11-21 Compass Therapeutics Llc Constructions de liaison à l'antigène immunomodulateur multispécifique
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
TW201730212A (zh) 2016-02-17 2017-09-01 宏觀基因股份有限公司 Ｒｏｒ１－結合分子及其使用方法
EP3419667A4 (en) 2016-02-26 2019-10-23 Imunexus Pty Ltd MULTISPECIFIC MOLECULES
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
TWI781098B (zh) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
CN109153727A (zh) 2016-04-15 2019-01-04 酵活有限公司 靶向免疫治疗剂的多特异性抗原结合构建体
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
SI3468586T1 (sl) 2016-06-14 2025-01-31 Xencor, Inc. Bispecifična protitelesa za zaviralce kontrolnih točk
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN105906722B (zh) 2016-06-24 2020-02-07 安徽未名细胞治疗有限公司 一种Her2特异性嵌合抗原受体及其应用
EP3507307A4 (en) 2016-09-01 2020-04-22 Immunomab, Inc. BISPECIFIC ANTIBODIES
US20190225702A1 (en) 2016-10-14 2019-07-25 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
WO2018148447A1 (en) 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3053275A1 (en) 2017-02-10 2018-08-16 Dragonfly Therapeutics, Inc. Proteins binding psma, nkg2d and cd16
MA47465A (fr) 2017-02-10 2019-12-18 Dragonfly Therapeutics Inc Protéines fixant le bcma, le nkg2d et le cd16
BR112019017256A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics Inc proteínas de ligação gd2, nkg2d e cd16
CA3054078A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding cd33, nkg2d and cd16
CA3054086A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding cd123, nkg2d and cd16
CN120173123A (zh) 2017-02-27 2025-06-20 蜻蜓疗法股份有限公司 靶向caix、ano1、间皮素、trop2、cea或紧密连接蛋白-18.2的多特异性结合蛋白
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
MX2019013998A (es) 2017-05-23 2020-07-29 Dragonfly Therapeutics Inc Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2).
KR20200010430A (ko) 2017-05-23 2020-01-30 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
AU2018273250A1 (en) 2017-05-23 2019-12-12 Dragonfly Therapeutics, Inc. A protein binding NKG2D, CD16 and a tumor-associated antigen
JP2019014449A (ja) 2017-07-10 2019-01-31 トヨタ自動車株式会社 車両用動力伝達装置
BR112020001972A2 (pt) 2017-07-31 2020-08-04 Dragonfly Therapeutics, Inc. proteínas de ligação a nkg2d, cd16 e flt3
AU2018318698A1 (en) 2017-08-16 2020-02-20 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16, and EGFR, HLA-E CCR4, or PD-L1
AU2018322178A1 (en) 2017-08-23 2020-02-20 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
SG10202102502VA (en) 2017-09-07 2021-04-29 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
SG11202002298PA (en) 2017-09-14 2020-04-29 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
EP3755348A4 (en) 2018-02-20 2022-03-02 Dragonfly Therapeutics, Inc. Antibody variable domains targeting cd33, and use thereof
US20220025037A1 (en) 2018-04-03 2022-01-27 Dragonfly Therapeutics, Inc. Antibody variable domains targeting dll3, and use thereof
EP3773676A4 (en) 2018-04-03 2022-05-18 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
EP3790585A4 (en) 2018-05-07 2022-05-11 Dragonfly Therapeutics, Inc. PROTEIN-BINDING NKG2D, CD16 AND TUMOR-ASSOCIATED ANTIGEN
WO2019222449A1 (en) 2018-05-16 2019-11-21 Dragonfly Therapeutics, Inc. Protein binding nkg2d, cd16 and a fibroblast activation protein
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
MX2021001510A (es) 2018-08-08 2021-07-02 Dragonfly Therapeutics Inc Proteínas de union a nkg2d, cd16, y un antígeno asociado a tumores.
AU2019366956B2 (en) 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
AU2020226493B2 (en) 2019-02-18 2025-10-23 Recourse Biologics, Inc. Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class l-like protein (OMCP) and tumor-specific binding partner
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
AU2020337999A1 (en) 2019-08-30 2022-03-24 Dragonfly Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind HER2, NKG2D, and CD16 for cancer treatment
MX2022004430A (es) 2019-10-15 2022-07-19 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3).
EP4045537A4 (en) 2019-10-15 2024-07-17 Dragonfly Therapeutics, Inc. Antibodies targeting flt3 and use thereof
US20230272041A1 (en) 2020-04-22 2023-08-31 Dragonfly Therapeutics, Inc. Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused Proteins
KR20230008157A (ko) 2020-05-06 2023-01-13 드래곤플라이 쎄라퓨틱스, 인크. 항체 표적화 clec12a 및 이의 사용
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
EP4192872B1 (en) 2020-08-05 2025-04-16 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and egfr
JP2023536627A (ja) 2020-08-05 2023-08-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｅｇｆｒを標的とする抗体およびその使用
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
WO2023056252A1 (en) 2021-09-29 2023-04-06 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and baff-r
JP2024537772A (ja) 2021-09-29 2024-10-16 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｂａｆｆ－ｒを標的化する抗体及びその使用
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
EP4476263A4 (en) 2022-02-09 2026-01-28 Dragonfly Therapeutics Inc PHARMACEUTICAL FORMULATIONS AND THERAPEUTIC USES OF MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO EGFR, NKG2D AND CD16
US20230416402A1 (en) 2022-03-03 2023-12-28 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002905A1 (en) 2005-06-29 2007-01-04 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
US20150210765A1 (en) * 2011-05-24 2015-07-30 Zyngenia, Inc. Multivalent and Monovalent Multispecific Complexes and Their Uses
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
US20170291955A1 (en) * 2014-04-11 2017-10-12 Medlmmune, Llc Bispecific her2 antibodies
WO2016090278A2 (en) 2014-12-05 2016-06-09 Avidbiotics Corp. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
WO2016134371A2 (en) 2015-02-20 2016-08-25 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
WO2016196237A1 (en) * 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2017081190A1 (en) 2015-11-13 2017-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
US20170368169A1 (en) * 2016-03-21 2017-12-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2018119171A1 (en) * 2016-12-23 2018-06-28 Potenza Therapeutics, Inc. Anti-neuropilin antigen-binding proteins and methods of use thereof
WO2018152518A1 (en) 2017-02-20 2018-08-23 Adimab, Llc Proteins binding her2, nkg2d and cd16
WO2019157332A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
WO2019157366A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
WO2019231920A1 (en) 2018-05-28 2019-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins and improvements thereon

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
ATWELL SRIDGWAY JBWELLS JACARTER P: "Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library", J. MOL. BIOL, vol. 270, no. 1, 1997, pages 26 - 35, XP002610109, DOI: 10.1006/jmbi.1997.1116
BLOMBERG ET AL., J. IMMUNOL. METHODS, vol. 193, no. 2, 1996, pages 199 - 206
C. GERMAIN ET AL., PROTEIN ENGINEERING DESIGN AND SELECTION, vol. 21, no. 11, 1 January 2008 (2008-01-01), pages 665 - 672
CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
ELLIOTT JMULTSCH MLEE JTONG RTAKEDA KSPIESS C ET AL.: "Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction", J. MOL. BIOL., vol. 426, no. 9, 2014, pages 1947 - 57, XP028844614, DOI: 10.1016/j.jmb.2014.02.015
H.-M. CHO ET AL., CANCER RESEARCH, vol. 70, 14 December 2010 (2010-12-14), pages 10121 - 10130
KABAT ET AL., J. BIOL. CHEM., vol. 252, 1977, pages 6609 - 6616
KABAT ET AL., SEQUENCES OF PROTEIN OF IMMUNOLOGICAL INTEREST, 1991
LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533
MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745
MARTIN A.: "Antibody Engineering", 2001, SPRINGER-VERLAG, article "Protein Sequence and Structure Analysis of Antibody Variable Domains", pages: 422 - 439
MARTIN: "Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY
MIMOTO FKADONO SKATADA HIGAWA TKAMIKAWA THATTORI K: "Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcyRs", MOL. IMMUNOL., vol. 58, no. 1, 2014, pages 132 - 8, XP028548629, DOI: 10.1016/j.molimm.2013.11.017
SONDERMANN ET AL., NATURE, vol. 406, no. 6793, pages 267 - 273
STEIMER ET AL., CLINICA CHIMICA ACTA, vol. 308, 2001, pages 33 - 41
U. BRINKMAN ET AL., MABS, vol. 9, no. 2, 10 January 2017 (2017-01-10), pages 182 - 212
VAKS ET AL.: "Design Principles for Bispecific IgGs, Opportunities and Pitfalls of Artificial Disulfide Bonds", ANTIBODIES, vol. 7, no. 3, 28 July 2018 (2018-07-28), pages 1 - 28, XP055549066, DOI: 10.3390/antib7030027 *
WANT ET AL., PROTEIN CELL, vol. 9, no. 1, 2018, pages 63 - 73
YOUNG ET AL.: "Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond", FEBS LETTERS, vol. 377, no. 2, 18 December 1995 (1995-12-18), pages 135 - 139, XP002520976, DOI: 10.1016/0014-5793(95)01325-3 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12129300B2 (en) 2018-02-08 2024-10-29 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
US12264200B2 (en) 2018-02-08 2025-04-01 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US11939384B1 (en) 2018-02-08 2024-03-26 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US12145976B2 (en) 2018-03-27 2024-11-19 Xyphos Biosciences Inc. Modified A1-A2 domains of non-natural NKG2D ligands that bind non-natural NKG2D receptors
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
US12275791B2 (en) 2018-08-08 2025-04-15 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
US12384851B2 (en) 2018-08-08 2025-08-12 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EP4021943A4 (en) * 2019-08-30 2023-09-13 Dragonfly Therapeutics, Inc. PHARMACEUTICAL FORMULATIONS AND DOSAGE REGIMENS FOR MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO HER2, NKG2D AND CD16 FOR THE TREATMENT OF CANCER
JP2022546454A (ja) * 2019-08-30 2022-11-04 ドラゴンフライ セラピューティクス， インコーポレイテッド がん処置のためのｈｅｒ２、ｎｋｇ２ｄおよびｃｄ１６に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン
WO2021224913A1 (en) * 2020-05-04 2021-11-11 Immunorizon Ltd. Precursor tri-specific antibody constructs and methods of use thereof
JP2024508894A (ja) * 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
EP4301774A4 (en) * 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
EP4476263A4 (en) * 2022-02-09 2026-01-28 Dragonfly Therapeutics Inc PHARMACEUTICAL FORMULATIONS AND THERAPEUTIC USES OF MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO EGFR, NKG2D AND CD16

Also Published As

Publication number Publication date
DK3833386T3 (da) 2023-09-04
CN112770769B (zh) 2024-07-12
US20250206827A1 (en) 2025-06-26
IL280656B1 (en) 2023-11-01
US12275791B2 (en) 2025-04-15
EP4249067A2 (en) 2023-09-27
EP4249067A3 (en) 2023-11-22
US20210198369A1 (en) 2021-07-01
JP2021533161A (ja) 2021-12-02
MY201987A (en) 2024-03-27
EA202091888A1 (ru) 2020-10-23
BR112021002213A2 (pt) 2021-07-20
SA521421188B1 (ar) 2024-07-25
AU2019318425A1 (en) 2021-03-04
EP3833386B1 (en) 2023-06-14
CA3108794A1 (en) 2020-02-13
ZA202100916B (en) 2024-08-28
KR20210042121A (ko) 2021-04-16
ES2954851T3 (es) 2023-11-27
DK3833386T5 (da) 2024-08-19
AU2019318425B2 (en) 2024-02-29
IL280656A (en) 2021-03-25
SG11202101276QA (en) 2021-03-30
KR102645411B1 (ko) 2024-03-11
EP3833386A4 (en) 2022-07-06
MX2021001508A (es) 2021-07-02
EA202190453A1 (ru) 2021-06-10
FI3833386T3 (fi) 2023-08-28
IL280656B2 (en) 2024-03-01
CN112770769A (zh) 2021-05-07
JP7431394B2 (ja) 2024-02-15
EP3833386A1 (en) 2021-06-16

Similar Documents

Publication Publication Date Title
US20250206827A1 (en) Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
AU2018329937B2 (en) Proteins binding nkg2d, cd16 and nectin4
CA3235295C (en) PROTEINS BINDING TO HER2, NKG2D AND CD16
US20240117054A1 (en) Proteins binding nkg2d, cd16 and flt3
EP4192872B1 (en) Proteins binding nkg2d, cd16 and egfr
CA3176049A1 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
AU2018331412A1 (en) Proteins binding NKG2D, CD16, and C-type lectin-like molecule-1 (CLL-1)
KR20250089564A (ko) 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
EP3579876A1 (en) Proteins binding bcma, nkg2d and cd16
CA3108427A1 (en) Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
WO2018148610A1 (en) Proteins binding psma, nkg2d and cd16
HK40053282B (en) Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
HK40053282A (en) Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
EA046929B1 (ru) Полиспецифические связывающие белки, которые связываются с her2, nkg2d и cd16, и способы их применения

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19847982

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3108794

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021506447

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021002213

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019318425

Country of ref document: AU

Date of ref document: 20190807

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019847982

Country of ref document: EP

Effective date: 20210309

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112021002213

Country of ref document: BR

Free format text: APRESENTE O COMPLEMENTO DO TEXTO EM PORTUGUES, ADAPTADO A NORMA VIGENTE, DO PEDIDO CONFORME DEPOSITO INTERNACIONAL INICIAL (RELATORIO DESCRITIVO E DESENHO, SE HOUVER), CONFORME DETERMINA A RESOLUCAO INPI PR NO 77/2013 DE 18/03/2013, ART. 5O E 7O

ENP Entry into the national phase

Ref document number: 112021002213

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210205

WWE Wipo information: entry into national phase

Ref document number: 521421188

Country of ref document: SA

WWG Wipo information: grant in national office

Ref document number: 521421188

Country of ref document: SA

WWG Wipo information: grant in national office

Ref document number: 17265876

Country of ref document: US